==== Front Genes Dis Genes Dis Genes & Diseases 2352-4820 2352-3042 Chongqing Medical University S2352-3042(22)00047-2 10.1016/j.gendis.2022.02.007 Review Article Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics Anand Uttpal a Dey Abhijit b1 Chandel Arvind K. Singh c1 Sanyal Rupa d Mishra Amarnath amishra5@amity.edu e∗∗ Pandey Devendra Kumar f De Falco Valentina g Upadhyay Arun h Kandimalla Ramesh ij Chaudhary Anupama k Dhanjal Jaspreet Kaur l Dewanjee Saikat m Vallamkondu Jayalakshmi n Pérez de la Lastra José M. jm.perezdelalastra@csic.es o∗ a Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel b Department of Life Sciences, Presidency University, Kolkata, West Bengal 700073, India c Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan d Department of Botany, Bhairab Ganguly College (affiliated to West Bengal State University), Kolkata, West Bengal 700056, India e Faculty of Science and Technology, Amity Institute of Forensic Sciences, Amity University Uttar Pradesh, Noida 201313, India f Department of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab 144411, India g Institute of Endocrinology and Experimental Oncology (IEOS), National Research Council (CNR), Department of Molecular Medicine and Medical Biotechnology (DMMBM), University of Naples Federico II, Naples 80131, Italy h Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandar Sindari, Kishangarh Ajmer, Rajasthan 305817, India i CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana 500007, India j Department of Biochemistry, Kakatiya Medical College, Warangal, Telangana 506007, India k Orinin-BioSystems, LE-52, Lotus Road 4, CHD City, Karnal, Haryana 132001, India l Department of Computational Biology, Indraprastha Institute of Information Technology Delhi (IIIT-D), Okhla Industrial Estate, Phase III, New Delhi 110020, India m Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India n Department of Physics, National Institute of Technology-Warangal, Warangal, Telangana 506004, India o Biotechnology of Macromolecules Research Group, Instituto de Productos Naturales y Agrobiología, IPNA-CSIC, San Cristóbal de La Laguna 38206, Tenerife, Spain ∗ Corresponding author. jm.perezdelalastra@csic.es ∗∗ Corresponding author. amishra5@amity.edu 1 Equal contribution. 18 3 2022 7 2023 18 3 2022 10 4 13671401 4 7 2021 15 2 2022 21 2 2022 © 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. 2022 Chongqing Medical University https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and produce aggressive malignancies that causes millions of deaths every year. With the new understanding of the molecular mechanism(s) of disease progression, our knowledge about the disease is snowballing, leading to the evolution of many new therapeutic regimes and their successive trials. In the past few decades, various combinations of therapies have been proposed and are presently employed in the treatment of diverse cancers. Targeted drug therapy, immunotherapy, and personalized medicines are now largely being employed, which were not common a few years back. The field of cancer discoveries and therapeutics are evolving fast as cancer type-specific biomarkers are progressively being identified and several types of cancers are nowadays undergoing systematic therapies, extending patients' disease-free survival thereafter. Although growing evidence shows that a systematic and targeted approach could be the future of cancer medicine, chemotherapy remains a largely opted therapeutic option despite its known side effects on the patient's physical and psychological health. Chemotherapeutic agents/pharmaceuticals served a great purpose over the past few decades and have remained the frontline choice for advanced-stage malignancies where surgery and/or radiation therapy cannot be prescribed due to specific reasons. The present report succinctly reviews the existing and contemporary advancements in chemotherapy and assesses the status of the enrolled drugs/pharmaceuticals; it also comprehensively discusses the emerging role of specific/targeted therapeutic strategies that are presently being employed to achieve better clinical success/survival rate in cancer patients. Keywords Antimicrobial peptides Cancer therapies Clinical trials Combination therapy Immunotherapy Patient survival Personalized medicine Targeted drug delivery ==== Body pmcIntroduction Cancer is a heterogeneous and multifactorial disease in which a series of genomic/molecular alterations cause the uncontrolled growth and proliferation of the cells, causing a rapid increase in tissue mass in the affected parts of the body. Under normal conditions, a cell gets signals to die and to supplant the organism with a young and healthier cell. Cancer cells grow using the body's oxygen and supplements, depriving other cells of regular supplements and growth factors. These cells can turn the microenvironment in their favor, deceive the immune system of the body, and can exploit the physiology of other cells to accommodate their needs.1, 2, 3, 4, 5, 6 Some of the biomarkers which are currently been used to detect cancer including human epididymis protein 4 (HE4), carcinoembryonic antigen (CEA), legumain, mesothelin, osteopontin, and vitamin E-binding plasma protein. A plethora of anti-cancer drugs and natural medicinal compounds have been devised over the years, which can suppress tumor growth through diverse mechanisms. Some of the drugs/compounds work on crucial cellular enzymes, while others may alter cell metabolism. They have also shown the potential to interfere with some critical cellular processes, e.g., programmed cell death/apoptosis, drug resistance, DNA damage, DNA replication, or immune reactions. These drugs have distinct modes of action and selectivity for multiple cancer types7, 8, 9, 10, 11, 12; however, subtle alteration to their chemical structure could abolish their anti-cancer potency.13,14 The idea of chemotherapy (utilizing toxic compounds and drugs to destroy cancerous cells) came into existence after the reports of mustard gas killing lymphatic tissues and bone marrow. The effects were later validated in mice using an effective derivative of the gas (nitrogen mustard) that showed effective regression of lymphoma tissues.15, 16, 17 The first patient receiving this nitrogen mustard was forty-eight years old lymphosarcoma patient whose cancer softened and cleared initially. Unfortunately, later he died after relapsing, but this secret military trial at Yale University paved the way for chemicals in treating cancers and developing the field of cancer chemotherapy for treating a variety of cancers.18, 19, 20, 21 Chemotherapy primarily works by circumventing the cancer cells from further growth and division. Cancer cells usually divide and grow at a much-accelerated rate than normal cells and are physiologically possess very high endogenous stress. Therefore, the drugs can destroy them rapidly and more effectively in comparison to other surrounding cells. Some of the promising inhibitor therapies which have been used to treat solid cancers are polyadenosine diphosphate-ribose polymerase inhibitors, angiogenesis inhibitors, histone deacetylase (HDAC) inhibitors, mechanistic target of rapamycin (mTOR) inhibitors, poly (adenosine di-phosphate-ribose) polymerase (PARP) inhibitors, p53/mouse double minute 2 homolog (MDM2) inhibitors, hedgehog pathway blockers, tyrosine kinase inhibitors and proteasome inhibitors.22,23 Chemotherapy may have different variations, which can affect the target cells in distinct manners.24 Some of the treatments may directly alter the quality of cellular proteins, rendering them non-functional and affecting major cellular physiological pathways. Major chaperone repressors, autophagy suppressors, or proteasome inhibitors belong to these classes of molecules.25, 26, 27, 28, 29, 30, 31 Other drugs may target some essential hormones and interfere with the body's overall metabolism.32,33 The 2018 Nobel Prize attributed to immune checkpoint therapy research has highlighted the importance of immunotherapy, which underlies the possibilities of modulating our immune system in our favor to cope up with the cancer-like conditions and fight back against the disease.24,34 The selection of chemo-preventive drugs or a combination of drugs is mostly based on the type and stage of cancer. The primary objective of these drugs is to neutralize the cancerous cells and ameliorate the stress caused by the tumor's growth. The dosage and timespan of the treatment are two important points of consideration. It has been observed that the medications are given at very high doses causing numerous side effects and harm to other healthy cells.35 One major challenge is the relapse of the disease. During reoccurrence, it has been widely observed that the cancer cells attain drug resistance following longer exposure to the drugs. Despite enormous applications, most chemotherapies are given to prolong and ease the patient's survival, hence called palliative chemotherapy.21 However, prolonged exposure to these drugs may have excessively adverse effects on a patient's physical and mental health, making it difficult to continue the ongoing treatment. Oncologists, for the most part, provide these medications with possible time intervals in between, which also gives non-transformed cells a chance to mend.36 In most cases, a team of specialists, including radiologists, nutritionists, psychologists, and the primary consultant collectively decide the treatment plans that include drug combinations, dosage, duration of cycles, and additional supplements. This report mainly reviews various aspects of cancer chemotherapy, including various applications of the drugs/chemotherapeutic agents that are already in practice. We also succinctly discussed various side effects and drawbacks of these treatment plans and further provided an overview of recent advancements in interventional strategies by focusing on targeted drug therapy, immunotherapy, personalized and integrative medicines. Figure 1 depicts the significant intrinsic and extrinsic cellular and molecular events causing the transformation of a normal cell to a cancer cell and its distinct hallmarks.Figure 1 Schematic diagram showing different intrinsic and extrinsic biological/molecular events potentiating the transformation of a normal cell to the cancer cell, while the lower part of this diagram showing different hallmarks of a transformed cancer cell. Fig. 1 Cancer chemotherapeutics: what is known so far? The idea of cancer as a disease was known to Hippocrates, the father of medicine, around 400 BC. He later coined the term ‘carcinos’ due to the similarity of cancer tissue growths with crabs. The term was later replaced with the Latin word cancer by Celsus. Many ancient pieces of literature have described several kinds of malignancies in humans, and multiple treatment approaches were also in use in different parts of the ancient world, as found in the literature of that era.37,38 However, the progress of strategies to treat the disease was more or less static until the beginning of the twentieth century.39 The extract of the plant Colchicum autumnale was used by Greek physicians to dissolve the tumor mass. Interestingly, in the 1930s, the active compound in the extract, colchicine, was reported that can interfere with microtubule assembly and may work as a potential drug.40 Vincristine and vinblastine are other similar compounds that were medicinally recognized as possible anti-tumor agents a long time ago.41 The ancient pieces of the literature suggest that the Greek and Roman physicians have contributed enormously to the identification and characterization of disease. Arabic, Indian, and Chinese medicinal archives have also paved the way for multiple medieval and modern approaches to understand and treat the disease. Interestingly, for centuries, most of the approaches remain limited to cauterization, bloodletting, surgery, herbal medicine, etc.42 In modern onco-medicine, which was evolved during the Second World War, many active compounds were reported following the detailed characterization of the disease at the genetic and molecular level. The initial decades have seen enormous debate on the use of cytotoxic agents as drug candidates; however, advancements were made, and success came in the form of Eli Lily introducing Vinca alkaloids in the 1960s, which was then followed by procarbazine.43 In the following years, the idea of combination therapy was introduced for acute lymphocytic leukemia and non-Hodgkin's lymphoma patients that were also supplemented with supportive medical care to enhance the quality of life.21 In the second half of the twentieth century, a series of reports have identified numerous mutations, external stimuli (toxic chemicals, viruses, etc.), metabolic alterations, etc. as the underlying causes of cancer.44,45 Identification of a plethora of cellular pathways that are affected in various cancer types has given different molecular alternatives to target and develop effective drugs (Fig. 2).46, 47, 48 Several modes of medications have also been introduced and tried for drug administration based on the types and stages of the diagnosed cancer. Here, we discuss the available drug medications, following which we have revisited the chemotherapeutic agents, which have substantially pushed the field forward and extended the lives of millions in the past several decades.Figure 2 Schematic diagram showing the basic principles of chemotherapy (A), different classes of chemotherapeutic agents/drugs (B), and immunotherapeutic mechanism(s) of targeting cancer cells (C). Fig. 2 Intravenous (IV) chemotherapy requires drug infusion straightforwardly into the patient's veins that may take from minutes to a few hours. Some medications can also be given either as pills or fluid regularly or at some intervals.49 Intramuscular shots and intra-abdominal administration are other methods of giving chemotherapeutic medications to target the specific locations of tumor mass.50 In addition, a new technology called pressurized intraperitoneal aerosol chemotherapy has been developed to efficiently deliver intraperitoneal chemotherapy for end-stage peritoneal metastases patients.51 Topical treatment methods imply providing drugs through the skin surface. The anti-cancer compounds derived from either natural sources or their synthetic chemical analogs can kill cancer cells or stop their development.52, 53, 54 Notably, various other approaches are emerging to treat the cancer cells, including small molecule inhibitors,55 a combination of anti-cancer agents and immunotherapy,56 nanotechnology-based drugs,57, 58, 59 and organo-seleno compounds (Fig. 2).31 Nevertheless, the selectivity of most drug particles is restricted, and such medications are considered one of the most harmful medications utilized in the treatment.60,61 Since the initial findings of modern anticancer drug discoveries in the 1940s, continuous efforts are being made to treat this life-threatening disease. Advances in scientific methods and techniques have brought new treatment and diagnostic tools and advanced patient care measures (Fig. 2).62, 63, 64, 65, 66, 67, 68, 69 Treatment plans may have palliation as one strategy that may lead to shrinkage of the obvious tumor, easing side effects, and increasing the life quality of patients. Figure 2 describes various ways of providing anti-cancer medications to patients depending upon their type and stage of the disease. Along with primary treatment, adjuvant therapy is also given to the patients for additionally combating the disease through supportive strategies.70,71 Surgery and radiation can be given to patients to supplement a chemotherapeutic plan to curb the disease by destroying shrouded cancer cells that could not be targeted otherwise.72 Sometimes adjuvant chemotherapy is given to patients after surgery or radiation or both to lessen the chances of recurrence.73, 74, 75 Adjuvant chemotherapy starts typically within three to five weeks of the surgical removal of a tumor and has distinctive treatment lengths relying upon the disease. Although chemotherapy has significantly improved overall survival, patients experience a wide range of physical and psychological symptoms that impact their quality of life. Symptoms seldom occur in isolation. Chemotherapy-induced hair loss remains greatly feared, with a negative impact on the well-being of many cancer patients. Cancer- and chemotherapy-induced poor appetite is usually the result of taste changes, mouth sores, nausea and vomiting, increased satiety, medication side effects, pain, fatigue, depressed mood, and anxiety. Basic principles of chemotherapy: years of research, miles to go The cancer cell metabolic mechanisms functionally overlap with the host cells, so cancer treatment is very challenging.76,77 Designing drugs or therapeutics mainly focuses on selectivity, which can specifically kill the cancerous cells without affecting the non-cancerous cells (Fig. 2). In a way, the anti-cancer therapy may resemble antimicrobials, but the cancerous cells and the bacterial cells have differences in terms of the metabolic and physiological characters.78, 79, 80 For our immune cells, bacterial cell recognition is straightforward, while our transformed cells can hide cell surface receptors to evade the immune system.81 Early-stage detection of cancers increases the chances of treatment and survival. Therefore, recognizing and diagnosing those transformed cells remains one of the most challenging tasks in oncological research. At early stages, most known biomarkers remain undetectable, and cancer cells' ability to hide from immune cells freezes our immune responses.82,83 In a tumor subpopulation, transformed cells differ drastically from the other cells in terms of physiology, metabolism, proliferation rate, etc.84, 85, 86 Besides that, the genetic diversity may pose additional challenges to target all kinds of cells in a particular tissue mass owing to the tumor heterogeneity.87,88 A combination of drug therapy is applied to address this challenge, and the regime is devised according to the cancer phase and type (Fig. 2).89,90 In the subsequent section, we provide a comprehensive overview of various chemotherapeutic agents which have served the purpose for several decades in different cancer types. These drugs could be classified in different ways based on their chemical nature/source, molecular target, mechanism/mode of action, or effectiveness in model systems against various malignancies/cancer types (Table 1).Table 1 Table listing chemotherapeutic drugs/agents used in current clinical practice along with details of their molecular targets, mode of action, and investigated model systems across diverse malignancies. Table 1Drugs/Compound Molecular targets Mechanism of action Studied model system Reference/Source Antineoplastic alkylating agents Altretamine DNA polymerase alpha catalytic subunit Ribonucleoside-diphosphate reductase large subunit DNA Inhibitor Inhibitor Other/unknow B-cell chronic lymphocytic, leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, and refractory non-Hodgkin's lymphoma 278 Bendamustine DNA Intra- and inter-strand crosslinking Chronic lymphocytic leukaemia (CLL), follicular non-Hodgkin's lymphoma refractory, refractory Hodgkin lymphoma, refractory Mantle cell lymphoma, Waldenström's macroglobulinemia (WM), recurrent multiple myeloma, and refractory indolent B cell non-Hodgkin lymphoma 279 Busulfan DNA Cross-linking/alkylation Chronic myelogenous leukemia 279 Carboplatin DNA Cross-linking/alkylation Advanced cervical cancer, advanced Endometrial Cancer, advanced esophageal cancers, advanced head and neck Cancer, advanced melanoma, advanced non-small cell lung cancer, advanced ovarian carcinoma, advanced Sarcoma, metastatic breast cancer, neuroendocrine carcinoma of the skin, pleural mesothelioma, refractory Hodgkin lymphoma, retinoblastoma, advanced bladder cancer, advanced small cell lung cancer, advanced testicular cancer, advanced thymoma, advanced thymic carcinoma, and refractory non-Hodgkin's lymphoma 279 Carmustine DNA Glutathione reductase, mitochondrial RNA Other/unknown inhibitor Other/unknown Glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma and metastatic brain tumors, multiple myeloma, Hodgkin's disease, non-Hodgkin's lymphomas, and may be used on the skin (topically) for cutaneous T-cell lymphoma 280 Chlorambucil DNA Cross-linking/alkylation Chronic lymphocytic leukemia, lymphomas, and Hodgkin's disease 279 Cisplatin DNA DNA-3-methyladenine glycosylase Alpha-2-macroglobulin Serotransferrin Copper transport protein ATOX1 Cross-linking/alkylation Not Available Not Available Not Available Not Available Testicular cancer, ovarian cancer, bladder cancer, head and neck cancer, esophagus cancer, small cell and non-small cell lung cancer, non-Hodgkin's lymphoma and trophoblastic neoplasms 279 Cyclophosphamide DNA Nuclear receptor subfamily 1 group I member 2 Cross-linking/alkylation Not Available Lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma. 279 Dacarbazine DNA DNA polymerase alpha subunit B 6-phosphogluconate dehydrogenase, decarboxylating Cross-linking/alkylation Other/unknown Inhibitor Melanoma skin cancer, soft tissue sarcoma, Hodgkin lymphoma 279 Daunorubicin DNA DNA topoisomerase 2-alpha DNA topoisomerase 2-beta Intercalation Inhibitor Inhibitor Acute nonlymphocytic leukemia in adults and acute lymphocytic leukemia in adults and children 279 Decitabine DNA DNA (cytosine-5)-methyltransferase 1 DNA (cytosine-5)-methyltransferase 3A DNA (cytosine-5)-methyltransferase 3B Other/unknown Inhibitor Inhibitor Inhibitor Myelodysplastic syndromes, and acute myeloid leukemia (AML) 279,281 Doxorubicin DNA DNA topoisomerase 2-alpha Nucleolar and coiled-body phosphoprotein 1 Intercalation Inhibitor Not available 279 Epirubicin DNA topoisomerase 2-alpha DNA Inhibitor Intercalation Breast cancer 279,282 Etoposide DNA topoisomerase 2-alpha DNA topoisomerase 2-beta inhibitor Inhibitor Testicular cancer, lung cancer, lymphoma, nonlymphocytic leukemia, neuroblastoma, and ovarian cancer, Kaposi's sarcoma, Ewing's sarcoma and glioblastoma multiforme 279 Idarubicin DNA DNA topoisomerase 2-alpha Intercalation Inhibitor Acute myelogenous, acute lymphoblastic and chronic myelogenous 279 Ifosfamide DNA Nuclear receptor subfamily 1 group I member 2 Other/unknown Not available Germ cell testicular cancer, soft tissue sarcoma, acute lymphocytic leukemia, bladder cancer, bone cancer, pancreatic cancer, stomach cancer, breast cancer, cervical cancer, endometrial cancer, lung cancer, ovarian cancer, neuroblastoma, lymphoma, and Wilms' tumor 279 Irinotecan DNA topoisomerase 1, DNA topoisomerase I, mitochondrial Inhibitor Inhibitor Metastatic colorectal cancer, other colorectal cancers and non-small/small lung cancers 279 Lomustine DNA Stathmin-4 Cross-linking/alkylation Antagonist Metastatic brain tumors, Hodgkin's and non-Hodgkin's lymphoma 279 Mechlorethamine DNA Intercalation Hodgkin's disease, chronic lymphocytic leukemia, chronic myelogenous leukemia, small cell lung cancer, medulloblastoma, and non-Hodgkin's lymphoma 283 Melphalan DNA Cross-linking/alkylation Multiple myeloma, ovarian cancer, breast cancer, melanoma, and amyloidosis 284 Mitomycin C DNA Cross-linking/alkylation Gastric cancer, anal and colon cancer, breast cancer, non-small cell lung cancer, head and neck cancer, small bladder papillomas, pancreatic cancer, cervical cancer 279 Mitoxantrone DNA DNA topoisomerase 2-alpha Intercalation Inhibitor Advanced, hormone-refractory prostate cancer, acute nonlymphocytic leukemia (ANLL), breast cancer and non-Hodgkin's lymphoma. 285 Oxaliplatin DNA Cross-linking/alkylation Metastatic or recurrent colorectal cancer, metastatic pancreatic cancer and metastatic gastric cancer. 286 Temozolomide DNA Cross-linking/alkylation Brain tumors (astrocytomas) in adult patients, metastatic melanoma and glioblastoma multiforme 287 Topotecan DNA topoisomerase 1 DNA topoisomerase I, mitochondrial DNA Inhibitor Inhibitor Intercalation Ovarian cancer, small cell lung cancer, and certain types of cervical cancer 288 Thiotepa DNA Cross-linking/alkylation Adenocarcinoma of the breast, adenocarcinoma of the ovary, papillary thyroid cancer and bladder cancer, Hodgkin's and non-Hodgkin's lymphomas 289 Trabectedin DNA Binder Soft tissue sarcoma, and ovarian cancer 290 Antineoplastic antimetabolites Azathioprine Ras-related C3 botulinum toxin substrate 1 Modulator Leukemia and lymphomas 291 Cladribine Ribonucleoside-diphosphate reductase large subunit Ribonucleoside-diphosphate reductase subunit M2 Ribonucleoside-diphosphate reductase subunit M2 B DNA DNA polymerase alpha catalytic subunit DNA polymerase epsilon catalytic subunit A DNA polymerase epsilon subunit 2 DNA polymerase epsilon subunit 3 DNA polymerase epsilon subunit 4 Purine nucleoside phosphorylase Inhibitor Inhibitor Inhibitor Other/unknown Inhibitor Inhibitor Inhibitor Inhibitor Inhibitor Inducer Drug-resistant T-cell prolymphocytic leukemia 292 Clofarabine DNA polymerase alpha catalytic subunit Ribonucleoside-diphosphate reductase large subunit DNA Inhibitor Inhibitor Other/unknown Relapsed or refractory acute lymphoblastic leukaemia, acute myeloid leukaemia, juvenile myelomonocytic leukaemia, and myelodysplastic syndrome 293 Fludarabine Ribonucleoside-diphosphate reductase large subunit DNA polymerase alpha catalytic subunit DNA Deoxycytidine kinase Inhibitor Inhibitor Incorporation into and destabilization Agonist Chronic lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and acute lymphocytic leukemia 294 Gemcitabine DNA Ribonucleoside-diphosphate reductase large subunit Thymidylate synthase UMP-CMP kinase Cross-linking/alkylation Inhibitor Inhibitor Inhibitor Breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer and bladder cancer 295 Mercaptopurine Hypoxanthine-guanine phosphoribosyltransferase Amidophosphoribosyltransferase Inosine-5′-monophosphate dehydrogenase Inhibitor Inhibitor Inhibitor Acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease and ulcerative colitis. 296 Nelarabine DNA DNA polymerase alpha catalytic subunit Incorporation into and destabilization Inhibitor Acute T-cell lymphoblastic leukemia 297 Pentostatin Adenosine deaminase inhibitor Hairy cell leukaemia refractory to alpha interferon 298 Tioguanine DNA Intercalation Acute leukemia 299 Pyrimidine-derived antimetabolites (pyrimidine antagonists) Capecitabine Thymidylate synthase DNA RNA Inhibitor Incorporation into and destabilization Incorporation into and destabilization Metastatic breast, gastric and colorectal cancers 99 Cytarabine DNA polymerase beta DNA Inhibitor Cross-linking/alkylation Acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML) and non-Hodgkin's lymphoma 97 Decitabine DNA DNA (cytosine-5)-methyltransferase 1 DNA (cytosine-5)-methyltransferase 3A DNA (cytosine-5)-methyltransferase 3B Other/unknown Inhibitor Inhibitor Inhibitor Myelodysplastic syndromes (MDS) 101 Gemcitabine DNA Ribonucleoside-diphosphate reductase large subunit Thymidylate synthase UMP-CMP kinase Cross-linking/alkylation Inhibitor Inhibitor Inhibitor Metastatic ovarian cancer, metastatic non-small cell lung cancer, and metastatic pancreatic adenocarcinoma 100 Fluorouracil Thymidylate synthase DNA RNA Other/unknown Incorporation into and destabilization Incorporation into and destabilization Actinic keratosis (AK), breast cancer, malignant neoplasm of colon, malignant neoplasm of pancreas, malignant neoplasm of stomach, rectal carcinoma, superficial basal cell carcinoma, and hyperkeratotic actinic keratosis 98 Raltitrexed Thymidylate synthase Folylpolyglutamate synthase, mitochondrial Inhibitor Antagonist Advanced Colorectal Cancer, Pleural Mesotheliomas 102 Tegafur Thymidylate synthase Inhibitor Advanced Gastric Cancer 103 Other antineoplastic agents (belong to one or multiple drug classes) Arsenic trioxide (Trisenox®) Inhibitor of nuclear factor Kappa-B kinase subunit beta Thioredoxin reductase 1, cytoplasmic Transcription factor AP-1 G1/S-specific cyclin-D1 Mitogen-activated protein kinase 3 Mitogen-activated protein kinase 1 inducer RAC-alpha serine/threonine-protein kinase Cyclin-dependent kinase inhibitor 1 Histone deacetylase 1 Protein PML Inducer Inhibitor Inducer Antagonist Inducer Inducer Inducer Not available Not available Not available Refractory Acute Promyelocytic Leukemia 300 Hydroxyurea Ribonucleoside-diphosphate reductase large subunit Inhibitor Melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia 301 Paclitaxel (Taxol®) Tubulin beta-1 chain Apoptosis regulator Bcl-2 Microtubule-associated protein 4 Microtubule-associated protein 2 Microtubule-associated protein tau Nuclear receptor subfamily 1 group I member 2 Inhibitor Inhibitor Not Available Not Available Not Available Inducer Kaposi's sarcoma and cancer of the lung, ovarian, and breast 302 Docetaxel (Taxotere®) Tubulin beta-1 chain Apoptosis regulator Bcl-2 Microtubule-associated protein 2 Microtubule-associated protein 4 Microtubule-associated protein tau Nuclear receptor subfamily 1 group I member 2 Not available Not available Not available Not available Not available Binder Locally advanced or metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer, hormone refractory metastatic prostate cancer, gastric adenocarcinoma and head and neck cancer 303 Ixabepilone (Ixempra®) Tubulin beta-3 chain Inhibitor Breast cancer, head and neck cancer, melanoma, lung cancer, non-Hodgkin's lymphoma, prostate cancer, renal cell carcinoma 279 Methotrexate Dihydrofolate reductase Humans Thymidylate synthase Bifunctional purine biosynthesis protein PURH Inhibitor Inhibitor Inhibitor Pediatric acute lymphoblastic leukemia, gestational choriocarcinoma, chorioadenoma destruens, breast cancer, epidermoid cancer of the head and neck, lung cancer, and advanced non-Hodgkin's lymphoma 304 Pemetrexed (Alimta®) Thymidylate synthase Bifunctional purine biosynthesis protein PURH Dihydrofolate reductase Trifunctional purine biosynthetic protein adenosine-3 Inhibitor Inhibitor Inhibitor Inhibitor Malignant pleural mesothelioma, and metastatic non-small cell lung cancer (NSCLC) 305 Streptozocin DNA Solute carrier family 2, facilitated glucose transporter member 2 O-GlcNAcase BT_4395 Bifunctional protein NCOAT Cross-linking/alkylation Ligand Antagonist Not available Malignant neoplasms of pancreas 306 Vinblastine Tubulin alpha-1A chain Tubulin beta chain Tubulin delta chain Tubulin gamma-1 chain Tubulin epsilon Transcription factor AP-1 Adduct Adduct Adduct Adduct Adduct Other/unknown Breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas and Kaposi's sarcoma 307 Vincristine Tubulin beta-1 chain Inhibitor Acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin's lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma, relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) 308 Vindesine Tubulin beta-1 chain Inhibitor Acute leukaemia, malignant lymphoma, Hodgkin's disease 309 Vinorelbine Tubulin beta chain Antagonist inhibitor Advanced non-small cell lung cancer (NSCLC), relapsed or refractory Hodgkin lymphoma, metastatic squamous cell head and neck cancer, recurrent ovarian cancer, metastatic breast cancer 310 Alkylating agents One major class of the current drugs belongs to alkylating agents, which can interfere with the formation/linkage of DNA double strands.91 These drugs can cause it by transferring one alkyl group to the guanidine base in DNA (Fig. 2). Cross-linking of nucleic acids with proteins or peptides can likewise affect the DNA geometry, cause erroneous base pairing and DNA strand breakage, and eventually preventing the cell division and causing irreversible senescence.92 Mechanistically, alkylating agents in their electrophilic forms interact with cellular DNA and form covalent adducts, underlying their broader utility. Therefore, alkylating drugs are the frontline chemotherapeutic agents given against most of the cancer types, yet the greatest therapeutic value of their inhibition is known for slow-growing cancers. In Table 1, we described the common chemotherapeutic alkylating agents including the altretamine, chlorambucil, platinum drugs (cisplatin, carboplatin, oxaliplatin), doxorubicin, epirubicin, etoposide, mitoxantrone, cyclophosphamide, thiotepa, and busulfan that are in clinical practice and also provided details of their molecular targets, mode of action, and studied model systems in various malignancies/cancer-types. Antimetabolites Antimetabolites are the next class of substances that may compete, replace, or inhibit some specific metabolites inside the cells and thus meddle with the cellular metabolism (Fig. 2).93 These molecules mostly possess a structure similar to a cellular metabolite or enzyme–substrate, usually identified and processed by an enzyme to meet the cellular needs.94 Tetrahydrofolates are formed from unreduced dietary folates by the enzyme dihydrofolate reductase. For example, various medications, such as aminopterin, methotrexate (amethopterin), pyrimethamine, trimethoprim, and triamterene, act directly on the production of these metabolites, hindering the enzyme from producing folate insufficiency.95 Methotrexate, an antifolate drug, is one of the exceptionally successful anti-cancer medications that represses dihydrofolate reductase (DHFR) and obstructs the transformation of dihydrofolic acid (DHFA) into tetrahydrofolic acid (THFA).96 This coenzyme activity is indispensable to the cells as they are essential for the nucleotide synthesis pathways. Methotrexate is an anti-inflammatory molecule and is hence used as a medication for many other inflammatory diseases, like rheumatoid arthritis and extreme psoriasis, apart from various cancer types. A detailed description of common antimetabolites is comprehensively provided in Table 1. Pyrimidine-derived antimetabolites (pyrimidine antagonists) and Vinca alkaloids Pyrimidine-derived antimetabolites are a group of chemotherapeutic agents that interrupt DNA synthesis and exert their cytotoxicity to cancer cells (Fig. 2). For instance, cytarabine also known as cytosine arabinoside or Ara C interrupts DNA as well as RNA synthesis by displacing the cytosine with itself (that differs merely by its base sugar arabinose). Cytarabine/cytosine arabinoside is enrolled frequently in clinics to treat leukemia or non-Hodgkin's lymphoma.97 Some other notably pyrimidine-derived antimetabolites include fluorouracil, 5-fluorouracil (5-FU), capecitabine, floxuridine, gemcitabine, decitabine, raltitrexed, and tegafur (Table 1).98, 99, 100, 101, 102, 103 Being as pyrimidine or purine analogs having altered chemical groups, these drugs/compounds induce apoptosis while progressing through the S phase of the cell cycle by their misincorporation to RNA and DNA or by inhibiting the key enzymes required for nucleic acid synthesis. Among these enzymes, DNA polymerases, ribonucleotide reductase, and thymidylate synthetase are the main intracellular targets of the pyrimidine antimetabolites. 5-FU has been a promising pyrimidine analog that largely interrupts DNA and RNA synthesis. 5-FU that dependents on its incorporation to DNA inhibits mitosis and stimulates cell death in the dividing cells. Vinca alkaloids, primarily extracted from several species under the Vinca genus, are mainly cell division inhibitors, which can interact with microtubular protein tubulin to obstruct its polymerization and meddle with the cytoskeleton, leading to stalling of mitotic division.104 The chromosomes do not separate efficiently during cell division, leading to metaphase capture. Vincristine and vinblastine are primary examples of this drug class with different degrees and ranges of anti-tumor activity (Table 1).105,106 Cancers treated with these drugs include acute leukemia, Hodgkin's and non-Hodgkin's lymphoma, rhabdomyosarcoma, Ewing's sarcoma, neuroblastoma, Wilms' tumor, miscellaneous myeloma, chronic leukemia, thyroid cancer, brain tumors, and several blood-related disorders.107 Other antineoplastic drugs/agents Besides these three established classes, several other antineoplastic agents are also enrolled in the clinical practice of cancer chemotherapy (Table 1). Given their clinical promises, in the subsequent section, we described the biological activities, targets, and mechanisms of key chemotherapeutic drugs that may belong to one or multiple drug classes and can affect more than one cellular pathway in the cancer cells and induce apoptosis by different mechanisms (Fig. 2). A succinct review of well-known anti-cancer drugs that are in routine clinical practice is provided as follows. Paclitaxel/Taxol It is a complex diterpene taxane ring-containing drug acquired from the bark of the Western yew tree (Taxus brevifolia), which induces cytotoxic activity by a novel system.108 It increases the polymerization of tubulin, thereby inducing a mechanism inverse to that of the aforementioned alkaloids.109 It forestalls the microtubule's structural adjustment and depolymerization, bringing an inherent cytotoxic activity to the paclitaxel due to the significance of tubulin-microtubule dynamics.110 The confirmed antagonistic impacts of paclitaxel are reported on the metastatic ovarian and bosom carcinomas after the disappointment from first-line chemotherapy and backslide cases.111 It has also shown efficacy against the advanced stage tumors of the head and neck disease, small cell lung cancer, oesophageal adenocarcinoma, and prostate cancer (Table 1).112,113 Docetaxel is a more potent relative of paclitaxel with a comparable activity. It has been shown to provide benefits against the bosom and ovarian cancers, which get resistant to first-line chemotherapeutic drugs.114 Unfortunately, many side effects have been reported from the long exposure to these drugs, which mainly include neutropenia, arrhythmia, neuropathy, and cardiovascular breakdown (Table 2).115,116Table 2 Table listing the adverse effects of various chemotherapy drugs, affected organs, their reported toxicities/side effects and current stage of their clinical progresses. Table 2Drugs/Compound Affected organ Reported toxicity/side effects (frequency in >30% cases) Current status Reference/Sources Alkylating agents/drugs Altretamine Blood Nausea and vomiting, Low blood counts, Peripheral neuropathy Approved 278 Bendamustine Blood Low blood counts, Increase in bilirubin levels Approved, Investigational 311,312 Busulfan Blood Low blood counts, Nausea and vomiting (usually mild with standard doses), Loss of fertility, Diarrhea (usually mild with standard doses), Poor appetite, Mouth sores Approved, Investigational 313,314 Carboplatin Cervix, skin, endometrium, esophagus, head and neck, lung, bladder, thymus, mesothelium, testicle Low blood counts, Nausea and vomiting, Taste changes, Hair loss, Weakness, Blood test abnormalities, abnormal magnesium level Approved 315 Carmustine Brain, skin Nausea and vomiting, Facial flushing, Pain and burning at the injection site, Low blood counts Approved, Investigational 280 Chlorambucil Blood Low blood counts Approved 316,317 Cisplatin Testicle, ovary, head-neck, lung, blood, esophagus, trophoblast Nausea and vomiting, Low blood counts, Kidney toxicity, Ototoxicity, Blood test abnormalities (low magnesium, low calcium, low potassium) Approved 318,319 Cyclophosphamide Blood, ovarian, breast, lung, brain Low blood counts, Hair loss, Nausea and vomiting, Poor appetite, Discoloration of the skin or nails Approved, Investigational 320 Dacarbazine Skin, blood Local pain, burning sensation and irritation at the needle site during the infusion, Low blood counts, Nausea and vomiting, Poor appetite, Elevation of blood liver enzymes Approved, Investigational 321,322 Daunorubicin Blood Pain along the site where the medication was given, Urine may appear red, red-brown, orange or pink from the color of the medication for one to two days after you receive a dose, Low blood counts, Nausea or vomiting, Hair loss on the scalp or elsewhere on the body Approved 323,324 Decitabine Blood Low blood counts, Fatigue, Fever, Nausea, Cough, Petechiae, Diarrhea, Constipation, Hyperglycemia Approved, Investigational 325 Doxorubicin Blood, breast, ovarian, bladder, stomach, bronchus Pain along the site where the medication was given, Nausea or vomiting, Low blood counts, Hair loss on the scalp or elsewhere on the body Approved, Investigational 326,327 Epirubicin Breast Low blood counts, Mouth sores, Hair loss on the scalp or elsewhere on the body, Nausea and vomiting, Fatigue, Amenorrhea Approved 321,328 Etoposide Testicle, lung, blood, brain, ovarian Low white blood cell count, Low platelet, Hair loss, Menopause, Loss of fertility, Nausea and vomiting Approved 122 Idarubicin Blood Pain along the site where the medication was given, Low blood counts, Urine may appear red, red-brown, orange or pink from the color of the medication for one to two days after you receive a dose, Nausea or vomiting, Mouth sores (in the first week after therapy), Hair loss on the scalp or elsewhere on the body, Diarrhea/abdominal cramps Approved 329 Ifosfamide Testicle, blood, bladder, bone, pancreas, cervix, breast, stomach, breast, endometrium, lung, ovary Low white blood cell count, Low platelet count, Hair loss, Nausea and vomiting, Poor appetite, Blood in the urine Approved 330 Irinotecan Colon, lung Diarrhea; two types early and late forms, Early diarrhea accompanied by symptoms runny nose, increased salivation, watery eyes, sweating, Fever, flushing, abdominal cramping, Late diarrhea, Nausea and vomiting, Weakness, Low white blood cell count, Low red blood cell count, Hair loss, Poor appetite, Weight loss Approved, Investigational 331 Lomustine Brain, blood Low blood counts (bone marrow suppression), Nausea and vomiting Approved, Investigational 332 Mechlorethamine or Chlormethine Blood, lung, brain Low blood counts, Nausea and vomiting, Hair loss, Mouth sores, Redness, dryness, irritation with topical use, Loss of fertility Approved, Investigational 15 Melphalan Blood, ovary, breast, skin Low blood counts, Nausea and vomiting Approved 333 Mitomycin C Stomach, intestine, breast, lung, bladder, pancreas, crevice Low blood counts, Mouth sores, Poor appetite, Fatigue Approved 137 Mitoxantrone Prostate, blood, breast Low blood counts, Nausea and vomiting, Fever, increases in blood tests measuring liver function Approved, Investigational 334 Oxaliplatin Intestine, pancreas, stomach Peripheral neuropathy, Nausea and vomiting, Diarrhea, Mouth sores, Low blood counts, Fatigue, Loss of appetite Approved, Investigational 335,336 Temozolomide Brain, skin Nausea and vomiting, Constipation, Headache, Fatigue Approved, Investigational 337 Topotecan Ovary, lung, cervice Low blood counts, Nausea and vomiting, Hair loss, Diarrhea Approved, Investigational 338, 339, 340 Thiotepa Breast, ovary, thyroid, bladder Low blood counts, Hair loss Approved, Investigational 341 Trabectedin Ovary Anemia, Increased liver enzymes, Low white blood cell count, Nausea, Low platelets, Vomiting, Fatigue, Low potassium, Low phosphorous, Decreased appetite, Constipation, Increased CPK Approved, Investigational 342,290 Purine antimetabolites (purine antagonists) Azathioprine Blood Black, tarry stools, Bleeding gums, Blood in the urine or stools, Chest pain, Chills, Cough, Fever, Hoarseness, Lower back or side pain, Painful or difficult urination, Pinpoint red spots on the skin, Sore throat, Sores, ulcers, or white spots on the lips or in the mouth, Swollen glands, unusual bleeding or bruising, unusual tiredness or weakness Approved 291 Cladribine Blood Fever, Fatigue, Low white blood cell count, Low red blood cell count, Neutropenic fever, Myelosuppression Approved, Investigational 343 Clofarabine Blood Leukopenia, Anemia, Infection, Limb pain, Lymphopenia, Low platelet count, Elevated liver enzymes, Vomiting, Nausea, Itching, Neutropenia, Diarrhea, Neutropenic fever, Creatinine increased, Bilirubin increased, Chills, Headache, Fever, Rash, High heart rate, Abdominal pain, Fatigue, Decreased appetite Approved, Investigational 293,344 Fludarabine Blood Low blood counts, Fever, Infection, Weakness, Cough, Nausea and vomiting, Poor appetite Approved 294 Gemcitabine Breast, ovary, lung, pancreas, bladder Flu-like symptoms (muscle pain, fever, headache, chills, fatigue), Fever (within 6–12 h of first dose), Fatigue, Nausea (mild), Vomiting, Poor appetite, Skin rash, Low blood counts, Temporary increases in liver enzymes, Blood or protein in the urine Approved, Investigational 295 Mercaptopurine Blood, intestine Low blood counts, Liver toxicity, Increased bilirubin, Increased liver enzymes, jaundice, abdominal swelling (ascites) Approved 345 Nelarabine Blood Low blood counts, also known as bone marrow suppression (anemia, Fatigue, neutropenia, thrombocytopenia), Nausea Approved, Investigational 297 Pentostatin Blood Cough or hoarseness, Fever or chills, Lower back or side pain, Painful or difficult urination, Skin rash or itching (sudden), Unusual tiredness or weakness Approved, Investigational 346 Thioguanine Blood Low blood counts Approved 347 Pyrimidine antimetabolites (pyrimidine antagonists) Capecitabine Breast, stomach, intestine Low white blood cell count, Low red blood cell count, Hand-foot syndrome, Diarrhea, Elevated liver enzymes, Fatigue, Nausea and vomiting, Rash and itching, Abdominal pain Approved, Investigational 99 Cytarabine Blood Headache, Low blood counts, nausea and vomiting, Mouth sores, increases in blood tests measuring liver function Approved, Investigational 97 Gemcitabine Breast, ovarian, lung, pancreas, bladder Flu-like, Fever, Fatigue, Nausea, Vomiting, Poor appetite, Skin rash, Low blood counts, Temporary increases in liver enzymes, Blood or protein in the urine Approved 348,349 Fluorouracil Breast, colon, pancreas, skin, stomach, rectal Diarrhea, Nausea and possible occasional vomiting, Mouth sores, Poor appetite, Watery eyes, sensitivity to light, Taste changes, metallic taste in mouth during infusion, Low blood counts, white and red blood cells and platelets may temporarily decrease, Skin reactions, Hair thinning, Hand -foot syndrome Approved 98 Raltitrexed Colon, mesothelium Increased risk of infection, Breathlessness and looking pale, Tiredness and weakness during and after treatment, Diarrhoea or constipation, Feeling or being sick, Skin problems, Mouth sores and ulcers, Tummy (abdominal) pain, Liver changes, Loss of appetite and weight loss, Dehydration Approved, Investigational 102 Tegafur Stomach Myelosuppression, Central neurotoxicity, Gastrointestinal toxicity Approved, Investigational 350 Other antineoplastic agents (belong to one or multiple drug classes) Arsenic trioxide (Trisenox®) Blood Nausea and vomiting, Cough, Fatigue, Fever, Headache, Rapid heartbeat, Sore throat, Abdominal pain, Diarrhea, Blood test abnormalities (low potassium and magnesium), Shortness of breath, Blurred vision and eye irritation, elevated blood sugar level, swelling of the face, hands, feet or legs, Difficulty sleeping, Rash, Heart rhythm changes, Joint pain, Itching, Numbness or tingling of hands or feet Approved 351,352 Hydroxyurea Skin, blood, ovary, breast Low blood counts Approved 301 Paclitaxel (Taxol®) Bone, lung, ovary, breast Low blood counts, Hair loss, Arthralgias and myalgias, pain in the joints and muscles, Peripheral neuropathy, Nausea and vomiting, Diarrhea, Mouth sores, Hypersensitivity reaction Approved, Vet Approved 353 Docetaxel (Taxotere®) Breast, lung, prostate, stomach Low white blood cell count, Low red blood cell count, Fluid retention with weight gain, swelling of the ankles or abdominal area, Peripheral neuropathy, Nausea, Diarrhea, Mouth sores, Hair loss, Fatigue and weakness, Infection, Nail changes Approved, Investigational 296 Ixabepilone (Ixempra®) Breast, skin, lung, blood, prostate, kidney Peripheral neuropathy, Weakness, Muscle and joint pains, Hair loss, Nausea and Vomiting, Low white blood cell count Approved, Investigational 354 Methotrexate Blood, breast chromium Dizziness, Drowsiness, Headache, Hair Loss, Swollen, Tender Gums Decreased Appetite, Reddened Eyes Approved 355 Pemetrexed (Alimta®) Pleura, lung Fatigue, Nausea Approved, Investigational 305 Streptozocin or Streptozotocin Pancreas Nausea and vomiting, Nephrotoxicity Approved, Investigational 356 Vinblastine Breast, blood, testicle, bone Low blood counts, Injection site reactions, Fatigue and weakness Approved 307 Vincristine Blood Hair loss, neurotoxicity, alopecia, myelosuppression Approved, Investigational 357 Vindesine or Eldisine Blood Myelosuppression, Neurotoxicity Approved, Investigational 358 Vinorelbine Lung, blood, ovary, breast Low blood counts, Nausea or vomiting, Muscle weakness, Constipation Approved, Investigational 359,360 Etoposide Etoposide is a semi-synthetic derivative of a plant glycoside called podophyllotoxin.117,118 It causes DNA damage by altering DNA topoisomerase-II function, and posing G2 cell cycle arrest.119 Etoposide creates a ternary complex with DNA and the topoisomerase–II complex, preventing the latter's binding to the DNA strands, while in doing so, it causes damage to DNA strands.120 Cancer cells depend on this enzyme more than healthy cells, as they divide more quickly; therefore, it causes defects in DNA synthesis that promotes apoptosis of the cancer cells.121 Etoposide is effective against several aggressive malignancies including Kaposi's sarcoma, Ewing's sarcoma, testicular disease, lung disease, lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme (Table 1).122 Camptothecin and its derivatives Camptothecin is a long-known topoisomerase inhibitory compound of natural origin. It was initially extracted from the bark of the tree Camptotheca acuminata.123,124 Camptothecin is a cytotoxic alkaloid comprised of a pentacyclic ring structure containing a pyrrole (3,4-β) quinoline moiety, an S-configured alpha-hydroxy lactone form, and a carboxylate form.125 In later years, many more effective derivatives of this topoisomerase inhibitor have been synthesized and are effectively being applied in cancer chemotherapy.126 The most recognized drug of this class, topotecan, is used against the advanced cancers of the ovary and lung. It targets topoisomerase-I, an enzyme responsible for easing the torsional strain in DNA by inducing single-strand breaks during replication.120 The inhibition of topoisomerase-I by the active compounds may lead to sudden inhibition of DNA replication and transcription, causing growth arrest (Table 1).127 In the physiological conditions, topotecan remains in equilibrium with its carboxylate structure.128 Its active lactone can intercalate between DNA bases in the topoisomerase-I cleavage complex.129 The coupling site of topotecan in the cleavage complex interferes with the topoisomerase-I while reiterating the scratched DNA strand in the wake of releasing the strain. Such intercalation traps the topoisomerase-I in the cleavage complex bound to the DNA.130 Another well-known drug of this class is irinotecan that has shown efficacy against late-stage colorectal carcinoma, aggressive growths in cancers of the lung, cervix, ovary, colon, etc.131,132 Actinomycin D (dactinomycin) A transcription inhibitor chromopeptide molecule actinomycin D (also called dactinomycin) binds to DNA while initiating transcription at initiation complex and inhibits RNA elongation steps.133 It can intercalate, preferably between guanidine and cytosine, or bind the DNA strand's minor grooves to form a highly stable drug-DNA complex, preventing DNA unwinding and thus stalling the progress of the RNA chain.134 Dactinomycin was initially obtained from Streptomyces sp., identified as an antibiotic agent, but later its anti-tumor potential was recognized, and thus it was inducted in the chemotherapy as an anticancer antibiotic to treat Ewing's sarcoma, Wilms' tumor, rhabdomyosarcoma, trophoblastic neoplasm, testicular and ovarian cancers, etc (Table 1).135 Mitomycin C Mitomycins, a class of natural quinones, are also derived from Streptomyces caespitosus and are known for their transformation and competence, enhancing potential in bacterial cells. It is also a known antineoplastic agent as it slows down fibroblast cell growth in glaucoma.136,137 These bioreductive alkylating agents (especially mitomycin C derivatives) are also utilized as anti-cancer therapeutics because their structural modification impedes the cell cycle during G1 and S phase transitions. Its reduction to form mitosene can lead to the N-alkylation of DNA bases.138 It can lead to inhibition of replication by cross-linking at adenine N6 and guanine O6 and N2.139 It is effectively used in the palliative treatment of non-small cell lung carcinoma and other solid tumors of breast, colorectal, oesophageal, pancreatic, and cervical origins. Porfiromycin is an N-methyl derivative of mitomycin C that is found effective against cancer of head and neck regions (Table 1).140 Daunorubicin (rubidomycin) Daunorubicin causes a break in DNA strands by actuating topoisomerase-II and producing quinone-type free radicals. Daunorubicin, otherwise called daunomycin, is a chemotherapy medicine used to treat cancer growth in acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma, etc.141,142 It is applied by infusion into a vein, and following its intercalation with DNA, it hinders macromolecular biosynthesis. This predominantly obstructs the movement of the enzyme topoisomerase-II, which loosens up the DNA supercoiling.143 Daunorubicin impedes the topoisomerase–II complex after it unties the DNA chain for replication and thereby it represses the DNA double helix from resealing and therefore interferes with the replication to proceed (Table 1).144,145 Bleomycin Another Streptomyces compound with anti-tumor activity bleomycin is mostly used against Hodgkin's lymphoma, ovarian and testicular cancers. It chelates copper or iron, produces superoxide radicals, and intercalates between DNA strands – causes chain scission.146 Emerging evidence proposes that bleomycin also hinders the consolidation of thymidine into DNA strands, and the cleavage of DNA relies upon oxygen and metal particles in vitro.147 The specific mechanism of DNA strand scission is uncertain, yet it has been proposed that bleomycin chelates metal particles (principally iron), delivering a pseudoenzyme that responds with oxygen to create superoxide and hydroxide free radicals that divide DNA; however, little myelosuppression is the unique highlight.148 The drug has also been effective against squamous cell carcinoma of the skin, and cancers of the mouth, head, neck, genitourinary tract, and throat (Table 1). Lateral damage: Putting multiple organs at risk Aggressive tumors are primarily marked with uncontrolled and extensive cell division that may compromise the normal physiology of other non-transformed cells in the vicinity of affected organs/tissues. In many ways, cancer cells achieve super-specialized metabolic and survival potential with the capacity to tolerate extreme stresses like low oxygen and nutrient supplies. Cancers might start from mutation of one type or the other, but as the disease progresses,149,150 multiple mutations and genetic abnormalities accumulate that lead to increased tumor heterogeneity.87 The heterogeneous nature of tumor mass plays a vital role in developing resistance against most of the drugs that we have described here. This leads to a challenge of its kind, leaving doctors with the only option of changing the medication after certain intervals as one type of drug stops acting against tumors. In many cases, the combination therapy that includes more than one drug at a time could be an effective strategy against some form/type of cancers, such as cancers affecting bone marrow (leukemia) and lymph nodes (lymphoma). Clinical trials help a lot in understanding the effects of new combinations and thus have rapidly improved the cancer chemotherapy paradigm. The sustainability of chemotherapy relies upon its continuous effect on cell division and tumor growth. As discussed above, the majority of the treatments work by compromising the stability or integrity of nucleic acids that tend to stall the cell cycle or activate programmed cell death pathways. Other drugs may act by generating extreme proteotoxic stress inside the cells by interfering with the protein folding or degradation machinery, including chaperone, proteasome, and autophagy.151, 152, 153, 154 The idea is to generate cellular stresses so that the cancer cells that are already under compromised physiology may die while other cells can survive. However, it is evident from the above descriptions that most of these drugs act by interfering with one or multiple cellular pathways of extreme importance.155 Therefore, chemotherapeutic drugs are mostly referred to as cytotoxic agents, causing a plethora of side effects. In most cases, long-term treatments may lead to enormous toxicity causing severe damage or failure of multiple organs. This may lead to enormous physiological and psychological stress to the patients under chemotherapeutic medication. Table 2 summarizes the adverse effects of various chemotherapeutic agents and the current stage of their clinical progress. The side effects of these drugs may depend on many factors and variables, such as type, stage, and location of the tumor, along with age, health, and other clinical aspects of the patients. The most common and readily visible side effects originate from the gut that may lead to nausea, vomiting, constipation, and diarrhea.156,157 Most of the anticancer drugs can directly interrupt the cell division pathways; therefore, the first line of affected organs may also include those which are formed with continuously dividing cells, such as skin, hair, and intestinal linings.158,148 Skin rashes, alopecia, and mucositis are the most visible side effects that one can observe in patients undergoing chemotherapy.157,159 Radiation also contributes significantly to these debilitating changes. A general problem observed in many patients is fatigue that can occur due to multiple factors, including depression, anemia, high doses of radiation therapy, etc.160 Chemotherapeutic drugs may also directly injure the bone marrow and cause a steep decline in blood cell count, exposing patients to several other types of possible infections.161 Thrombocytopenia, a condition of excessive bleeding because of lower platelet numbers, is observed more frequently in patients taking alkylating and/or antimetabolites agents.162 Alkylating agents may further trigger conditions, such as hemorrhagic cystitis leading to microscopic haematuria, nocturia, dysuria, etc. along with mild or intense suprapubic pain.163 Whereas, antimetabolites can generate enormous toxicity in vital organs, like the liver and kidneys.164,165 The most devastating of all is their direct impact on cardiovascular health. Different classes of chemotherapeutic drugs have varying impacts on cardiac cells, leading to multiple types of systemic conditions adversely affecting patients' survival.166 Loss of libido and sexual dysfunctions are other conditions caused due to long-term exposure to these drugs, which affects not only physical well-being but also the patient's psychological health (Table 2).167,168 These drugs and radiation therapies may have several direct or indirect impacts on cognitive functioning leading to a condition, which is now commonly referred to as chemo brain.169,170 This is a condition of the inability of someone undergoing chemo-drug therapies to do their routine cognitive functions, which may be related to their memory, cognition, and behavior.171 The drugs may adversely impact communication, reasoning, learning, problem-solving, memory storage, concentration, following commands, etc. Damage of optic and the ocular motor nerves is also observed in several patients taking antineoplastic drugs that may lead to the weakening of vision as well.172,173 The majority of chemotherapeutic agents affect these tissues in a dose-dependent manner; though, there are differences in their sensitivity to individuals due to enormous factors such as metabolism efficiency, genetic makeup, other medication, and environmental factors (Table 2).174 Despite enormous toxicities and side effects prevalent in the public domain, the chemotherapy medicines remained the most immediate and viable therapeutic option in most cases, where we can see the cancer cells but cannot remove them through surgery or source of radiation. To address various above-described detrimental physical and psychological changes, modern-day clinical practices involve a comprehensive team of doctors and specialists for the patients who are undergoing long-term treatments and are more prone to develop severe physiological complications. Recent advancements and next-generation therapeutic approaches Since the early 19th century, rigorous investigations and clinical studies were carried out around the world. Several research groups have made landmark discoveries during and after the Second World War. Following the development of a fundamental description of the disease and associated pathways, the focus shifted majorly towards advancing the diagnosis and treatment methods of the disease. Despite enormous progress being made in the second half of the last century, not much could have been achieved in successfully curing most of the cancers. One primary reason behind the failures is our inability to diagnose the oncogenic changes inside the body at the early stages of cancer development. In recent years, the concept of liquid biopsies has emerged that primarily relies on the screening of mutated DNAs, proteins, RNAs, and other genetic markers in the patient's blood samples.175, 176, 177 This practice can help diagnose the disease at a much earlier stage than we do now, using the traditional tissue biopsies and imaging methods.178 New technological tools, like advanced software and robotic platforms, have also speeded cancer diagnosis and treatment. In this subsequent section taking chemotherapy into account, we compressively reviewed the recent progress made in the targeted drug delivery, personalized medication, and immunotherapy (Fig. 3).Figure 3 Schematic diagram showing targeted cancer therapeutic approaches. (A) Model showing targeted drug delivery approach of anti-cancer drugs/chemical agents conjugated with receptor substrate specific to the cancer cell receptor. (B) Model showing the building of a personalized medicine approach based on omics data and drug response study targeting specific mutation/signature in individual patients for precision cancer therapeutics. (C) Model showing immunotherapeutic regime involving reprogramming of T-cells to target cancer cells by a chimeric antigen receptor for their application in cancer immunotherapy. Fig. 3 Targeted drug delivery The major drawback of most chemotherapeutic treatment plans is their non-specificity or inability to ascertain and target cancerous cells directly. Therefore, this lack of specificity poses a major therapeutic limit reflected in the failure of delivering drugs locally to the cancer tissue mass. In the past few decades, many new approaches have been constituted and tested, and have given hopes for future drug delivery (Fig. 3A). Nanoparticle-based delivery methods, targeted antibodies, aptamer functionalization, and specific drugs like Herceptin (in breast cancer) offered the promise that can harness great success in the upcoming years.179, 180, 181 Cancer cell-directed antibodies are at the forefront of targeted drug delivery methods and have accelerated the hunt for more effective or potentially improvised approaches.182,183 Different types of nanocarriers and formulations of nano-drugs have also improved the delivery of drug compounds to the cancer cells.184, 185, 186 The most significant advantage of targeted drug deliveries is that the enormous drug-mediated toxicities on other adjacent tissues and organs can be minimized. We can also avoid most of the collateral damage leading to stress and organ failures. However, the effectiveness of many of these delivery methods in patients is still under clinical evaluation. Further details regarding these delivery systems can be accessed in the previously published reports.187,188 Personalized medication Given the heterogeneity of tumor cells, the cancer of one patient is different from that of another in terms of accumulated genetic abnormalities, its pace and progression, the response to the treatment, and the chances of developing resistance to the administered drugs.45 The current technologies have made it possible to get insights into this disease heterogeneity or explore molecular variations at the individual level, thereby tailoring the treatment regime as per the personalized needs of every cancer patient.149,189 This helps in choosing the most appropriate drugs and their dosages for a better outcome in cancer management.190 For instance, dabrafenib and vemurafenib are directed against BRAF gene mutation, while trastuzumab works well against HER-2 mutated cells.47,191,192 The idea here is to dive deep into the omics (genomic, transcriptomic, proteomic, metabolomic, etc.) data of the patient to identify the major molecular players fostering the transformed cells, and design the treatments against these clinically actionable targets (Fig. 3B).155,193,194 Different types of mutations have been observed to be frequent in specific subtypes of cancer. Therefore, measuring and manipulating these driver mutations based on an individual patient is expected to yield better results. Following are some examples of drugs that are potentially effective in patients harbouring some specific type of genomic alteration. A mutation in anaplastic lymphoma kinase (ALK) was reported to drive tumor formation in 5% of the non-small-cell lung cancer population and led to the discovery of ALK blockers such as crizotinib and ceritinib.195 An oral BRAF inhibitor, namely vemurafenib has been shown to possess a greater affinity for the mutant BRAFV600E than the wildtype BRAF, and therefore was recommended to the patients carrying the above mutation in the tumors.196 Several potential targets for novel drugs have been identified using high-throughput screening technologies, and various compounds against them have been recently approved or are under investigation. Similarly, alterations in phosphoinositide 3-kinases (PI3K)/protein kinase B (AKT)/mTOR pathway have also been frequently found in many solid tumors. Among these, activation of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and loss of phosphatase and tensin homolog (PTEN) mutations are the most common. Basket trials have been conducted to evaluate the effectiveness of adding alpelisib, a specific p110α PIK3CA inhibitor to the hormonal treatment for PIK3CA mutant luminal breast cancer patients. The results emphasize the importance of checking for this molecular alteration in patients and following the tested treatment regime for better anti-tumor response.193 Next, aberrant changes in the fibroblast growth factors (FGF) signaling pathway have also been associated with the initiation and progression of oncogenic events. Different types of genetic alterations in FGF receptor amplification, mutations, and gene-fusion have been shown to respond variably to certain drugs, and hence demand molecular profiling for the selection of effective drugs.46,197 Another promising example is of using poly ADP ribose polymerase (PARP) inhibitor olaparib for the treatment of breast cancer susceptibility gene (BRCA)-mutant cancers for better targeting of cancer cells, without much effect on the normal cells.198,199 On the cytoprotective side, recently a natural alkylated withanolide viz. 2,3-Dihydro-3beta-methoxy withaferin-A was shown to protect normal cells against a variety of stresses enrolled in cancer therapeutics.200 The idea of precision or personalized medicine is new but has been beneficial for lots of patients; however, the cost of these new generation approaches for genome profiling is still high, making it unaffordable for a large population of the world.201 Antimicrobial peptides Advances in cancer therapy have prompted scientists to look for natural tumoricidal chemicals, such as antimicrobial peptides (AMPs), that could be used for cancer treatment.202, 203, 204 In addition to antibacterial action, several AMPs have been shown to have intrinsic anticancer potential.205,206 These molecules constitute an intriguing new resource for anticancer drugs, and they provide several distinct therapeutic advantages over other anticancer treatments since they do not bind directly to any particular receptor in cancer cells.207 The polycationic and amphipathic character of AMPs has been postulated as a possible explanation for the preferential interaction of AMPs with cancer cells, as compared to normal cells.208,209 Membrane disruption has been identified as a critical stage in the microbial killing mechanism of several AMPs. These anticancer effects of AMPs are unaffected by molecular heterogeneity inside a tumor or across tumors, nor are they counteracted by cancer cells' flexibility and alternate survival pathways, as is commonly found in cancer resistance (Fig. 4).204,209,210Figure 4 Advantages of antimicrobial peptides as anti-tumor agents. Fig. 4 Cathelicidins are members of the antimicrobial peptide family found in granules of vertebrate neutrophils.211 The only human cathelicidin is the cationic peptide LL-37. Cathelicidins are composed of a highly conserved N-terminal signal peptide including a cathelin domain and a C-terminal cationic antimicrobial peptide. Apart from their antimicrobial activity, cathelicidin-derived antimicrobial peptides exhibit a range of biological roles, including antiviral, antifungal, anticancer, and immunomodulatory properties.212,213 LL-37 exhibits anticancer activity against oral cancer cells and has been identified as a molecular target for colon cancer.214 Immunohistochemical staining of colon cancer tissue showed that LL-37 is abundantly expressed in normal colon mucosa but downregulated in colon cancer tissues due to DNA methylation in the LL-37 promoter.215 In human oral squamous cell carcinoma SAS-H1 cells, the active domain of LL-37 induces mitochondrial depolarization, which results in caspase-independent apoptosis. Furthermore, mice lacking cathelicidin are more susceptible to azoxymethane-induced colon carcinogenesis.216 Many important advancements have been achieved using antimicrobial peptides against colorectal cancer.217 Using LL-37 on the surface of magnetic nanoparticles led to a significant reduction in cell viability of colon cancer cell lines, inducing apoptosis at a much higher rate than in the case of LL-37 peptide alone.218 Fan et al created a biodegradable and injectable thermosensitive hydrogel containing docetaxel and LL-37 polymeric nanoparticles. Intraperitoneal injection of this hydrogel substantially inhibited the development of HCT116 carcinomatosis in a mouse model of colorectal carcinoma.219 In comparison to existing chemotherapeutic agents, the flexible nature of peptide structures, along with non-receptor activity, might confer strategic benefits on AMPs for the treatment of colon cancer in the future.220 New treatment approaches for patients with advanced-stage, unresectable melanomas continue to be of significant clinical interest, as these patients cannot be treated surgically and have only a modest or temporary response to chemotherapy and radiation. In phase 1 clinical trial NCT02225366, intra-tumoral injections of LL-37 are being explored for melanoma patients with cutaneous metastases to determine the most effective dose of LL-37 that could be administered. Patients will receive weekly intra-tumoral injections of LL-37 (starting dose, 250 μg/tumor) every 7 days for up to 8 weeks. Researchers are also interested in understanding whether LL37 can activate the immune system, which could help in the control of the disease.221 Although AMPs have the potential to develop into a more effective and safer alternative to conventional cancer therapy, future research and development of anticancer peptide therapeutics will most likely focus on the poor pharmacokinetics, the control of selectivity, toxicity, and routes of administration through the establishment of appropriate in vivo models.222 Immunotherapy Supplementing our immune system by devising immunotherapy strategies is another highly-specific and largely promising approach to address the problem of late-stage cancer therapeutics.223,224 Several new approaches have been developed in the last decade to modify and train a patient's immune system to search, identify and target the transformed cells inside the body by recognizing multiple cell surface markers.225 For instance, supplementing the treatment regime with immunotherapy has significantly improved the success rate of the chemotherapeutic drugs in many cancer types, especially the triple-negative breast cancers.226, 227, 228 The immunotherapy drugs are given alone or in combination with chemotherapy drugs to achieve better clinical outcomes.229 Prophylactic and therapeutic vaccines have been developed to help patients' immune systems towards learning to tackle the transformed cells.230 Atezolizumab is an example of an anti-cancer immune drug that helps to dissolve hard-to-treat breast cancers.231, 232, 233 Tisagenlecleucel, an FDA-approved drug, treats B-cell lymphoblastic leukemia by effectively engineering the chimeric T cell receptor (CAR-T) of the patient (Fig. 3C).234 Some treatment plans also include interferons and interleukins to jump-start the fight against cancer cells by boosting the patient's immune system. Moreover, the field of immunotherapy is gradually evolving and is beyond the scope of our present article. Combination therapy Combination therapy may offer the advantages of the fast tumor regression of targeted therapies with the long-lasting responses induced by immunotherapy.235 Immunotherapy may be able to consolidate the dramatic tumor responses achieved with targeted therapy into durable, long-lasting remissions, in which sustained host responses targeting multiple antigens may reduce the risk of developing potentially lethal drug-resistant clones.236 Combining cancer vaccines with immune checkpoint inhibitors (ICIs) such as those targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) is one approach to avoid T cell anergy.237,238 Moreover, T-cell and NK-cell invasion may be facilitated by targeted drugs that modify the tumor endothelium.239 Gemcitabine, for example, is a deoxycytidine analog that induces tumor cell death, which results in antigen cross-presentation and cross-priming.240,241 Carboplatin, pemetrexed, and pembrolizumab are now commonly used in the treatment of non-small cell lung cancer as first-line agents.242 For triple-negative breast cancer, nab-paclitaxel and atezolizumab (anti-PD-L1) were recently authorized based on an improvement in progression-free survival (PFS) over chemotherapy.243 Adenosine receptor antagonists (ARs) are involved in regulating tumor progression.244 The four ARs discovered so far, A1, A2A, A2B and A3, belong to the class A family of G protein-coupled receptors (GPCRs).245 The A2BR seems more promising as a target in chemotherapeutic interventions,246 whereas the A2AR is the main target in the immunotherapeutic approach.247,248 The existence of dual compounds, i.e., molecules acting on the A2AR and on the A2BR, has prompted their use in both immunotherapeutic and chemotherapeutic interventions.249,250 Epigenetic modulators may have a dual function in the tumor microenvironment, boosting both antigen expression and T cell effector activity.251,252 ICI-induced reactivation of exhausted T cells is linked with considerable chromatin remodeling, indicating that epigenetic modification may relieve certain patients with exhausted T cell function.253,254 While many strategies focus on modifying the native tumor microenvironment, an alternative strategy involves the direct infusion of engineered immune cells or cellular receptors into the patient via adoptive cellular therapy with the goal of increasing the number of effector cells that recognize tumor-expressed antigens.255 Upon reinfusion, lymphocytes grown ex vivo may respond more potently to tumor antigen since they have not been continuously exposed to tolerogenic microenvironmental signals.256 Tumor infiltrating lymphocytes (TIL) treatment,257 chimeric antigen receptor (CAR) engineered T-cells,258,259 and TCR-engineered cell therapy260,261 are the three main forms of adoptive T cell therapy currently being investigated.257,262,263 Injecting oncolytic viruses directly into the tumor microenvironment is an alternate technique for improving tumor antigen recognition and strengthening T cell responses.264 Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus that is injected intra-lesionally into the melanoma tumor in individuals who have failed to get their tumor removed. It induces immediate lysis of tumor cells and the production of granulocyte-macrophage colony-stimulating factor (GM-CSF), which serves as a cytokine to stimulate the recruitment, maturation, and activity of antigen presenting cells (APCs).265 Several studies combining immunotherapy with molecularly targeted treatment, either concurrently or sequentially, have shown hepatotoxicity as a major concern.266 Combinations of dabrafenib, trametinib, and anti-PD-1 treatment have been associated with a greater risk of grade 3/4 adverse events in melanoma than would be expected with targeted therapy alone.256 Emerging drugs are beginning to take a more comprehensive perspective of the tumor microenvironment (TME) and are revealing complementary techniques to simultaneously restore and enhance immune activity and promote therapeutic synergy.267,268 Future research of combined therapy should continue to concentrate on exploring the intricate interplay between targeted drugs and immunotherapy, as well as optimizing parameters such as administration time, dose, and sequencing that may enhance the therapeutic index.240 Conclusions and future perspectives Chemotherapy is a largely investigated and clinically assessed approach in cancer therapeutics. In this report, we summarized the present status of chemotherapy and several drugs/agents presently enrolled in the clinical practice to provide an overview of how the field has evolved over the years and has traced the possibilities and druggability of diverse cancers in the clinic. New trends are evolving in the drug discovery paradigm that includes designing new derivatives of old drugs with high efficacy and lower toxicities.269,270 Several natural compounds isolated from microbial, plants, or natural sources were suggested to hold enormous potential to target stress response pathways by mounting a hyperactive response instigating cancer cell death.271, 272, 273, 274 Natural compounds/agents as chemotherapeutic drugs demonstrated several advantages over synthetic ones, owing to their less cytotoxicity, cost, and straightforward production/extraction process.273,275,276 Therefore, recognition and attenuation of treatment toxicity in cancer chemotherapy will be a key factor in determining the success of its regimes in the future. Revised clinical strategies further underlined that combination therapy could emerge as a promising therapeutic approach to treat diverse cancers in the future. Combination strategies comprise an obvious overlap of the chemotherapeutic regimes with the targeted drug delivery, personalized medicine, and immunotherapy. It may not only improve the efficacy of enrolled treatment but can also elicit the responsiveness of certain tumors towards their effective therapeutic targeting in the clinic. Among these, personalized combination therapies that target individual tumor types based on their molecular signatures may offer a great promise. With acquiring more personalized insights in the chemotherapeutic treatments, a greater emphasis will be on individual regimes that could meet a high clinical success.277 Therefore, chemotherapy beyond its conventional clinical efficacy offers to improve the clinical outcome in combination therapies. Translation of these combined approaches in the clinics is yet to see a complete success and thus warrants more clinical investigations. Conclusively, clinical practice of cancer chemotherapy has achieved considerable success, however, it still holds scope to improve, particularly in terms of efficacy and safety of enrolled chemotherapeutic regimes. Therefore, it further requires concerted efforts and careful investigations assessing the efficacy of combined therapeutic regimes. In summary, more investigative focus on drug design in individual or combined regimes and rigor on their clinical trials involving careful patient selection and stratification are warranted to achieve the greater therapeutic success of chemotherapeutic regimens in the clinic. Conflict of interests The authors declare no conflict of interests. Funding This research was funded by "Agencia Canaria de Investigación, Innovación y Sociedad de la Información (10.13039/501100007757 ACIISI ) del Gobierno de Canarias” (No. ProID2020010134), and óCaja Canarias (Project No. 2019SP43). Acknowledgements All the authors are highly grateful and acknowledge to the authority of the respective departments and institutions for their support in carrying out this research. The authors also express their sincere gratitude to the unknown referee for critically reviewing the manuscript and suggesting useful changes. Peer review under responsibility of Chongqing Medical University. ==== Refs References 1 Janssen L.M.E. Ramsay E.E. Logsdon C.D. Overwijk W.W. The immune system in cancer metastasis: friend or foe? J Immunother Cancer 5 1 2017 79 29037250 2 Laplagne C. Domagala M. le Naour A. Latest advances in targeting the tumor microenvironment for tumor suppression Int J Mol Sci 20 19 2019 4719 31547627 3 Emon B. Bauer J. Jain Y. Jung B. Saif T. Biophysics of tumor microenvironment and cancer metastasis - a mini review Comput Struct Biotechnol J 16 2018 279 287 30128085 4 Costa A. Scholer-Dahirel A. Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment Semin Cancer Biol 25 2014 23 32 24406211 5 Gilbert S. Oliphant C. Hassan S. ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival Oncogene 38 2 2019 194 208 30087439 6 Pfirschke C. Siwicki M. Liao H.W. Pittet M.J. Tumor microenvironment: no effector T cells without dendritic cells Cancer Cell 31 5 2017 614 615 28486102 7 Bedoui S. Herold M.J. Strasser A. Emerging connectivity of programmed cell death pathways and its physiological implications Nat Rev Mol Cell Biol 21 11 2020 678 695 32873928 8 Rodrigues D. Souza T. Jennen D.G.J. Lemmens L. Kleinjans J.C.S. de Kok T.M. Drug-induced gene expression profile changes in relation to intestinal toxicity: state-of-the-art and new approaches Cancer Treat Rev 77 2019 57 66 31279169 9 Delou J.M.A. Souza A.S.O. Souza L.C.M. Borges H.L. Highlights in resistance mechanism pathways for combination therapy Cells 8 9 2019 1013 31480389 10 Kalra R.S. Bapat S.A. Enhanced levels of double-strand DNA break repair proteins protect ovarian cancer cells against genotoxic stress-induced apoptosis J Ovarian Res 6 1 2013 66 24044516 11 Caccuri F. Sommariva M. Marsico S. Inhibition of DNA repair mechanisms and induction of apoptosis in triple negative breast cancer cells expressing the human herpesvirus 6 U94 Cancers 11 7 2019 1006 31323788 12 Kalra R.S. Bapat S.A. Expression proteomics predicts loss of RXR-γ during progression of epithelial ovarian cancer PLoS One 8 8 2013 e70398 23936423 13 Huang C. Vaishnavi K. Kalra R. 3β-methoxy derivation of withaferin-a attenuates its anticancer potency: bioinformatics and molecular evidences Med Aromatic Plants 4 219 2015 2167-0412 14 Chaudhary A. Kalra R.S. Malik V. 2, 3-dihydro-3β-methoxy withaferin-A lacks anti-metastasis potency: bioinformatics and experimental evidences Sci Rep 9 1 2019 17344 31757995 15 Chen Y. Jia Y. Song W. Zhang L. Therapeutic potential of nitrogen mustard based hybrid molecules Front Pharmacol 9 2018 1453 30618747 16 Needham D.M. Cohen J.A. Barrett A.M. The mechanism of damage to the bone marrow in systemic poisoning with mustard gas Biochem J 41 4 1947 631 639 16748227 17 Ghanei M. Delayed haematological complications of mustard gas J Appl Toxicol 24 6 2004 493 495 15558826 18 Cairns J. The treatment of diseases and the war against cancer Sci Am 253 5 1985 51 59 4071033 19 Duffy M.J. The war on cancer: are we winning? Tumour Biol 34 3 2013 1275 1284 23568704 20 Christakis P. The birth of chemotherapy at Yale. Bicentennial lecture series: surgery Grand Round Yale J Biol Med 84 2 2011 169 172 21698052 21 DeVita V.T. Jr. Chu E. A history of cancer chemotherapy Cancer Res 68 21 2008 8643 8653 18974103 22 Sawyers C. Targeted cancer therapy Nature 432 7015 2004 294 297 15549090 23 Dewanjee S. Vallamkondu J. Kalra R.S. The emerging role of HDACs: pathology and therapeutic targets in diabetes mellitus Cells 10 6 2021 1340 34071497 24 Mattheolabakis G. Rigas B. Constantinides P.P. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives Nanomedicine 7 10 2012 1577 1590 23148540 25 Leu J.I.J. Pimkina J. Pandey P. Murphy M.E. George D.L. HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells Mol Cancer Res 9 7 2011 936 947 21636681 26 Wu W.K. Wu Y.C. Yu L. Li Z.J. Sung J.J. Cho C.H. Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells Biochem Biophys Res Commun 374 2 2008 258 263 18638451 27 Selimovic D. Porzig B.B.O.W. El-Khattouti A. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells Cell Signal 25 1 2013 308 318 23079083 28 Hasima N. Ozpolat B. Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer Cell Death Dis 5 2014 e1509 25375374 29 Sannino S. Guerriero C.J. Sabnis A.J. Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells J Cell Sci 131 17 2018 jcs217760 30131440 30 Zhu K. Dunner K. Jr. McConkey D.J. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells Oncogene 29 3 2010 451 462 19881538 31 Chen J. Chen X. Xu D. Autophagy induced by proteasomal DUB inhibitor NiPT restricts NiPT-mediated cancer cell death Front Oncol 10 2020 348 32292717 32 Stewart D.A. Winnike J.H. McRitchie S.L. Clark R.F. Pathmasiri W.W. Sumner S.J. Metabolomics analysis of hormone-responsive and triple-negative breast cancer cell responses to paclitaxel identify key metabolic differences J Proteome Res 15 9 2016 3225 3240 27447733 33 Sun H. Zhang A.H. Liu S.B. Cell metabolomics identify regulatory pathways and targets of magnoline against prostate cancer J Chromatogr B Analyt Technol Biomed Life Sci 1102–1103 2018 143 151 34 Kroemer G. Zitvogel L. Immune checkpoint inhibitors J Exp Med 218 3 2021 e20201979 35 Torino F. Barnabei A. Paragliola R. Baldelli R. Appetecchia M. Corsello S.M. Thyroid dysfunction as an unintended side effect of anticancer drugs Thyroid 23 11 2013 1345 1366 23750887 36 Mahner S. Eulenburg C. Staehle A. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials Eur J Cancer 49 1 2013 142 149 22921185 37 di Lonardo A. Nasi S. Pulciani S. Cancer: we should not forget the past J Cancer 6 1 2015 29 39 25553086 38 Papac R.J. Origins of cancer therapy Yale J Biol Med 74 6 2001 391 398 11922186 39 Morrison W.B. Cancer chemotherapy: an annotated history J Vet Intern Med 24 6 2010 1249 1262 20840315 40 Riddle J.M. Ancient and medieval chemotherapy for cancer Isis 76 3 1985 319 330 3902714 41 Lee C.T. Huang Y.W. Yang C.H. Huang K.S. Drug delivery systems and combination therapy by using Vinca alkaloids Curr Top Med Chem 15 15 2015 1491 1500 25877096 42 Lau Y.C. Lip G.Y.H. New advances in the treatment of atrial fibrillation: focus on stroke prevention Expet Opin Pharmacother 15 15 2014 2193 2204 43 DeVita V.T. Hellman S. Rosenberg S.A. Cancer, Principles & Practice of Oncology 11th ed. 2018 Lippincott Williams & Wilkins Philadelphia, PA 44 Hanahan D. Weinberg R.A. Hallmarks of cancer: the next generation Cell 144 5 2011 646 674 21376230 45 Caon I. Bartolini B. Parnigoni A. Revisiting the hallmarks of cancer: the role of hyaluronan Semin Cancer Biol 62 2020 9 19 31319162 46 Dieci M.V. Arnedos M. Andre F. Soria J.C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives Cancer Discov 3 3 2013 264 279 23418312 47 Holderfield M. Deuker M.M. McCormick F. McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Nat Rev Cancer 14 7 2014 455 467 24957944 48 Kalra R.S. Chaudhary A. Yoon A.R. CARF enrichment promotes epithelial-mesenchymal transition via Wnt/β-catenin signaling: its clinical relevance and potential as a therapeutic target Oncogenesis 7 5 2018 39 29748568 49 Chua T.C. Yan T.D. Saxena A. Morris D.L. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? : a systematic review of morbidity and mortality Ann Surg 249 6 2009 900 907 19474692 50 Jin J.F. Zhu L.L. Chen M. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection Patient Prefer Adherence 9 2015 923 942 26170642 51 Giger-Pabst U. Bucur P. Roger S. Comparison of tissue and blood concentrations of oxaliplatin administrated by different modalities of intraperitoneal chemotherapy Ann Surg Oncol 26 13 2019 4445 4451 31399820 52 Lichota A. Gwozdzinski K. Anticancer activity of natural compounds from plant and marine environment Int J Mol Sci 19 11 2018 3533 30423952 53 Weaver B.A. How Taxol/paclitaxel kills cancer cells Mol Biol Cell 25 18 2014 2677 2681 25213191 54 Omar A. Kalra R.S. Putri J. Elwakeel A. Kaul S.C. Wadhwa R. Soyasapogenol-A targets CARF and results in suppression of tumor growth and metastasis in p53 compromised cancer cells Sci Rep 10 1 2020 6323 32286347 55 Sun G. Rong D. Li Z. Role of small molecule targeted compounds in cancer: progress, opportunities, and challenges Front Cell Dev Biol 9 2021 694363 34568317 56 Apetoh L. Ladoire S. Coukos G. Ghiringhelli F. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol 26 9 2015 1813 1823 25922066 57 Piktel E. Niemirowicz K. Wątek M. Wollny T. Deptuła P. Bucki R. Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy J Nanobiotechnol 14 1 2016 39 58 Anand U. Carpena M. Kowalska-Góralska M. Safer plant-based nanoparticles for combating antibiotic resistance in bacteria: a comprehensive review on its potential applications, recent advances, and future perspective Sci Total Environ 2022 153472 35093375 59 Kaur K. Reddy S. Barathe P. Combating drug-resistant bacteria using photothermally active nanomaterials: a perspective review Front Microbiol 12 2021 747019 34867863 60 Mitra A.K. Agrahari V. Mandal A. Novel delivery approaches for cancer therapeutics J Contr Release 219 2015 248 268 61 Large D.E. Soucy J.R. Hebert J. Auguste D.T. Advances in receptor-mediated, tumor-targeted drug delivery Adv Ther 2 1 2019 1800091 62 Yarchoan M. Agarwal P. Villanueva A. Recent developments and therapeutic strategies against hepatocellular carcinoma Cancer Res 79 17 2019 4326 4330 31481419 63 Vaidyanathan R. Soon R.H. Zhang P. Jiang K. Lim C.T. Cancer diagnosis: from tumor to liquid biopsy and beyond Lab Chip 19 1 2018 11 34 30480287 64 Bera K. Schalper K.A. Rimm D.L. Velcheti V. Madabhushi A. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology Nat Rev Clin Oncol 16 11 2019 703 715 31399699 65 Charmsaz S. Prencipe M. Kiely M. Pidgeon G.P. Collins D.M. Innovative technologies changing cancer treatment Cancers 10 6 2018 208 29921753 66 Markham M.J. Wachter K. Agarwal N. Clinical cancer advances 2020:annual report on progress against cancer from the American society of clinical oncology J Clin Oncol 38 10 2020 1081 32013670 67 Jaffee E.M. van Dang C. Agus D.B. Future cancer research priorities in the USA: a lancet oncology commission Lancet Oncol 18 11 2017 e653 e706 29208398 68 Zhao J. Dean D.C. Hornicek F.J. Yu X. Duan Z. Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy Cancer Lett 474 2020 158 167 31987920 69 Coccia M. Deep learning technology for improving cancer care in society: new directions in cancer imaging driven by artificial intelligence Technol Soc 60 2020 101198 70 Patel S. Emerging adjuvant therapy for cancer: propolis and its constituents J Diet Suppl 13 3 2016 245 268 25723108 71 Grob J.J. Garbe C. Ascierto P. Larkin J. Dummer R. Schadendorf D. Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? Lancet Oncol 19 12 2018 e720 e725 30507438 72 Benson A.B. 3rd Schrag D. Somerfield M.R. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer J Clin Oncol 22 16 2004 3408 3419 15199089 73 Matei D. Filiaci V. Randall M.E. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer N Engl J Med 380 24 2019 2317 2326 31189035 74 Cao L. Xu C. Cai G. How does the interval between completion of adjuvant chemotherapy and initiation of radiotherapy impact clinical outcomes in operable breast cancer patients? Ann Surg Oncol 28 4 2021 2155 2168 32974696 75 Salazar M.C. Rosen J.E. Wang Z. Association of delayed adjuvant chemotherapy with survival after lung cancer surgery JAMA Oncol 3 5 2017 610 619 28056112 76 Kalyanaraman B. Teaching the basics of cancer metabolism: developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism Redox Biol 12 2017 833 842 28448945 77 Moore A. Metabolic cycles in cancer cells? Bioessays 42 4 2020 e2000048 32189387 78 Anand U. Jacobo-Herrera N. Altemimi A. Lakhssassi N. A comprehensive review on medicinal plants as antimicrobial therapeutics: potential avenues of biocompatible drug discovery Metabolites 9 11 2019 258 31683833 79 Alibek K. Bekmurzayeva A. Mussabekova A. Sultankulov B. Using antimicrobial adjuvant therapy in cancer treatment: a review Infect Agents Cancer 7 1 2012 33 80 Shoshan-Barmatz V. Anand U. Nahon-Crystal E. di Carlo M. Shteinfer-Kuzmine A. Adverse effects of metformin from diabetes to COVID-19, cancer, neurodegenerative diseases, and aging: is VDAC1 a common target? Front Physiol 12 2021 730048 34671273 81 Nicholson L.B. The immune system Essays Biochem 60 3 2016 275 301 27784777 82 Gonzalez H. Hagerling C. Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression Genes Dev 32 19–20 2018 1267 1284 30275043 83 Whiteside T.L. Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol 3 2013 107 23730621 84 Kreuzaler P. Panina Y. Segal J. Yuneva M. Adapt and conquer: metabolic flexibility in cancer growth, invasion and evasion Mol Metabol 33 2020 83 101 85 Yoshida G.J. Metabolic reprogramming: the emerging concept and associated therapeutic strategies J Exp Clin Cancer Res 34 2015 111 26445347 86 Wadhwa R. Kalra R.S. Kaul S.C. CARF is a multi-module regulator of cell proliferation and a molecular bridge between cellular senescence and carcinogenesis Mech Ageing Dev 166 2017 64 68 28754531 87 Mroz E.A. Rocco J.W. The challenges of tumor genetic diversity Cancer 123 6 2017 917 927 27861749 88 Gambara G. Gaebler M. Keilholz U. Regenbrecht C.R.A. Silvestri A. From chemotherapy to combined targeted therapeutics: in vitro and in vivo models to decipher intra-tumor heterogeneity Front Pharmacol 9 2018 77 29491834 89 Palmer A.C. Sorger P.K. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy Cell 171 7 2017 1678 1691 e13 29245013 90 Ke X. Shen L. Molecular targeted therapy of cancer: the progress and future prospect Front Lab Med 1 2 2017 69 75 91 Kondo N. Takahashi A. Ono K. Ohnishi T. DNA damage induced by alkylating agents and repair pathways J Nucleic Acids 2010 2010 543531 21113301 92 Qiu H. Wang Y. Exploring DNA-binding proteins with in vivo chemical cross-linking and mass spectrometry J Proteome Res 8 4 2009 1983 1991 19714816 93 Mehrmohamadi M. Jeong S.H. Locasale J.W. Molecular features that predict the response to antimetabolite chemotherapies Cancer Metabol 5 2017 8 94 Katzung B.G. Basic and Clinical Pharmacology 10th ed. 2008 McGraw-Hill Singapore 95 Lambie D.G. Johnson R.H. Drugs and folate metabolism Drugs 30 2 1985 145 155 3896745 96 Raimondi M.V. Randazzo O. la Franca M. DHFR inhibitors: reading the past for discovering novel anticancer agents Molecules 24 6 2019 1140 30909399 97 Löwenberg B. Pabst T. Vellenga E. Cytarabine dose for acute myeloid leukemia N Engl J Med 364 11 2011 1027 1036 21410371 98 Grem J.L. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development Invest N Drugs 18 4 2000 299 313 99 Masuda N. Lee S.J. Ohtani S. Adjuvant capecitabine for breast cancer after preoperative chemotherapy N Engl J Med 376 22 2017 2147 2159 28564564 100 Dyawanapelly S. Kumar A. Chourasia M.K. Lessons learned from gemcitabine: impact of therapeutic carrier systems and gemcitabine's drug conjugates on cancer therapy Crit Rev Ther Drug Carrier Syst 34 1 2017 63 96 28322141 101 Malik P. Cashen A.F. Decitabine in the treatment of acute myeloid leukemia in elderly patients Cancer Manag Res 6 2014 53 61 24520204 102 Liu Y. Wu W. Hong W. Sun X. Wu J. Huang Q. Raltitrexed-based chemotherapy for advanced colorectal cancer Clin Res Hepatol Gastroenterol 38 2 2014 219 225 24388340 103 Hasegawa K. Saiura A. Takayama T. Oral adjuvant chemotherapy using uracil-tegafur (UFT) with leucovorin (LV) after resection of colorectal cancer liver metastases: long-term survival results of the phase III UFT/LV study J Clin Oncol 35 2017 672 104 Moudi M. Go R. Yien C.Y. Nazre M. Vinca alkaloids Int J Prev Med 4 11 2013 1231 1235 24404355 105 Bates D. Eastman A. Microtubule destabilising agents: far more than just antimitotic anticancer drugs Br J Clin Pharmacol 83 2 2017 255 268 27620987 106 Habli Z. Toumieh G. Fatfat M. Rahal O.N. Gali-Muhtasib H. Emerging cytotoxic alkaloids in the battle against cancer: overview of molecular mechanisms Molecules 22 2 2017 250 28208712 107 Falzone L. Salomone S. Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium Front Pharmacol 9 2018 1300 30483135 108 Schneider F. Pan L. Ottenbruch M. List T. Gaich T. The chemistry of nonclassical taxane diterpene Acc Chem Res 54 10 2021 2347 2360 33942612 109 Fanale D. Bronte G. Passiglia F. Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? Anal Cell Pathol 2015 2015 690916 110 Leung J.C. Cassimeris L. Reorganization of paclitaxel-stabilized microtubule arrays at mitotic entry: roles of depolymerizing kinesins and severing proteins Cancer Biol Ther 20 10 2019 1337 1347 31345098 111 Schwab C.L. English D.P. Roque D.M. Santin A.D. Taxanes: their impact on gynecologic malignancy Anti Cancer Drugs 25 5 2014 522 535 24300913 112 Abu Samaan T.M. Samec M. Liskova A. Kubatka P. Büsselberg D. Paclitaxel's mechanistic and clinical effects on breast cancer Biomolecules 9 12 2019 789 31783552 113 Zhu L. Chen L. Progress in research on paclitaxel and tumor immunotherapy Cell Mol Biol Lett 24 2019 40 31223315 114 Mahalaxmi I. Devi S.M. Kaavya J. Arul N. Balachandar V. Santhy K.S. New insight into NANOG: a novel therapeutic target for ovarian cancer (OC) Eur J Pharmacol 852 2019 51 57 30831081 115 Postma T.J. Vermorken J.B. Liefting A.J. Pinedo H.M. Heimans J.J. Paclitaxel-induced neuropathy Ann Oncol 6 5 1995 489 494 7669713 116 Das T. Anand U. Pandey S.K. Therapeutic strategies to overcome taxane resistance in cancer Drug Resist Updates 55 2021 100754 117 Stähelin H.F. von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain memorial Award lecture Cancer Res 51 1 1991 5 15 1988106 118 Green J.A. Tarpey A.W. Warenius H.M. Pharmacokinetic study of high dose etoposide infusion in patients with small cell lung cancer Acta Oncol 27 6b 1988 819 822 2852947 119 Infante Lara L. Fenner S. Ratcliffe S. Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences Nucleic Acids Res 46 5 2018 2218 2233 29447373 120 Pommier Y. Leo E. Zhang H. Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem Biol 17 5 2010 421 433 20534341 121 Bruni E. Reichle A. Scimeca M. Bonanno E. Ghibelli L. Lowering etoposide doses shifts cell demise from caspase-dependent to differentiation and caspase-3-independent apoptosis via DNA damage response, inducing AML culture extinction Front Pharmacol 9 2018 1307 30483138 122 Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor Eur J Cancer 34 10 1998 1514 1521 9893622 123 Wall M.E. Camptothecin and taxol: discovery to clinic Med Res Rev 18 5 1998 299 314 9735871 124 Martino E. Della Volpe S. Terribile E. The long story of camptothecin: from traditional medicine to drugs Bioorg Med Chem Lett 27 4 2017 701 707 28073672 125 Yu S. Huang Q.Q. Luo Y. Lu W. Total synthesis of camptothecin and SN-38 J Org Chem 77 1 2012 713 717 22165912 126 Li F. Jiang T. Li Q. Ling X. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Am J Cancer Res 7 12 2017 2350 2394 29312794 127 Guo Y. Shi M. Shen X. Yang C. Yang L. Zhang J. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis Clin Colorectal Cancer 13 2 2014 110 118 24461997 128 Herben V.M. ten Bokkel Huinink W.W. Beijnen J.H. Clinical pharmacokinetics of topotecan Clin Pharmacokinet 31 2 1996 85 102 8853931 129 Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond Nat Rev Cancer 6 10 2006 789 802 16990856 130 Tomicic M.T. Christmann M. Kaina B. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival Cancer Res 65 19 2005 8920 8926 16204064 131 Bailly C. Irinotecan: 25 years of cancer treatment Pharmacol Res 148 2019 104398 31415916 132 Sawada S. Yokokura T. Miyasaka T. Synthesis of CPT-11 (irinotecan hydrochloride trihydrate) Ann N Y Acad Sci 803 1996 13 28 8993496 133 Sobell H.M. Actinomycin and DNA transcription Proc Natl Acad Sci USA 82 16 1985 5328 5331 2410919 134 Avendaño C. Menéndez J.C. Medicinal Chemistry of Anticancer Drugs 2008 Elsevier Amsterdam 135 Arndt C. Hawkins D. Anderson J.R. Breitfeld P. Womer R. Meyer W. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide J Clin Oncol 22 10 2004 1894 1901 15143082 136 Al-Hazmi A. Zwaan J. Awad A. Al-Mesfer S. Mullaney P.B. Wheeler D.T. Effectiveness and complications of mitomycin C use during pediatric glaucoma surgery Ophthalmology 105 10 1998 1915 1920 9787364 137 Crooke S.T. Bradner W.T. Mitomycin C: a review Cancer Treat Rev 3 3 1976 121 139 786455 138 Tomasz M. Mitomycin C: small, fast and deadly (but very selective) Chem Biol 2 9 1995 575 579 9383461 139 Noll D.M. Mason T.M. Miller P.S. Formation and repair of interstrand cross-links in DNA Chem Rev 106 2 2006 277 301 16464006 140 Haffty B.G. Wilson L.D. Son Y.H. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial Int J Radiat Oncol Biol Phys 61 1 2005 119 128 15629602 141 Murphy T. Yee K.W.L. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia Expet Opin Pharmacother 18 16 2017 1765 1780 142 Tan C. Tasaka H. Yu K.P. Murphy M.L. Karnofsky D.A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia Cancer 20 3 1967 333 353 4290058 143 Fornari F.A. Randolph J.K. Yalowich J.C. Ritke M.K. Gewirtz D.A. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells Mol Pharmacol 45 4 1994 649 656 8183243 144 Bodley A. Liu L.F. Israel M. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA Cancer Res 49 21 1989 5969 5978 2551497 145 Zhang G. Fang L. Zhu L. Syntheses and biological activities of disaccharide daunorubicins J Med Chem 48 16 2005 5269 5278 16078845 146 Yu Z. Yan B. Gao L. Targeted delivery of bleomycin: a comprehensive anticancer review Curr Cancer Drug Targets 16 6 2016 509 521 26632436 147 Lown J.W. Sim S.K. The mechanism of the bleomycin-induced cleavage of DNA Biochem Biophys Res Commun 77 4 1977 1150 1157 71149 148 Weber G.F. DNA damaging drugs Molecular Therapies of Cancer 2015 Springer Cham. 149 Meldrum C. Doyle M.A. Tothill R.W. Next-generation sequencing for cancer diagnostics: a practical perspective Clin Biochem Rev 32 4 2011 177 195 22147957 150 Kalra R.S. Cheung C.T. Chaudhary A. Prakash J. Kaul S.C. Wadhwa R. CARF (Collaborator of ARF) overexpression in p53-deficient cells promotes carcinogenesis Mol Oncol 9 9 2015 1877 1889 26278998 151 Joshi V. Upadhyay A. Prajapati V.K. Mishra A. How autophagy can restore proteostasis defects in multiple diseases? Med Res Rev 40 4 2020 1385 1439 32043639 152 Mishra R. Upadhyay A. Prajapati V.K. Mishra A. Proteasome-mediated proteostasis: novel medicinal and pharmacological strategies for diseases Med Res Rev 38 6 2018 1916 1973 29719055 153 Upadhyay A. Amanullah A. Chhangani D. Joshi V. Mishra R. Mishra A. Ibuprofen induces mitochondrial-mediated apoptosis through proteasomal dysfunction Mol Neurobiol 53 10 2016 6968 6981 26666667 154 Na Y. Kaul S.C. Ryu J. Stress chaperone mortalin contributes to epithelial-mesenchymal transition and cancer metastasis Cancer Res 76 9 2016 2754 2765 26960973 155 Bapat S.A. Krishnan A. Ghanate A.D. Kusumbe A.P. Kalra R.S. Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer Cancer Res 70 12 2010 4809 4819 20530682 156 Stringer A.M. Gibson R.J. Logan R.M. Irinotecan-induced mucositis is associated with changes in intestinal mucins Cancer Chemother Pharmacol 64 1 2009 123 132 18998135 157 Thorpe D. Stringer A. Butler R. Chemotherapy-induced mucositis: the role of mucin secretion and regulation, and the enteric nervous system Neurotoxicology 38 2013 101 105 23827812 158 Mitchison T.J. The proliferation rate paradox in antimitotic chemotherapy Mol Biol Cell 23 1 2012 1 6 22210845 159 McQuade R.M. Stojanovska V. Abalo R. Bornstein J.C. Nurgali K. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments Front Pharmacol 7 2016 414 27857691 160 Bower J.E. Cancer-related fatigue: mechanisms, risk factors, and treatments Nat Rev Clin Oncol 11 10 2014 597 609 25113839 161 Wang Y. Probin V. Zhou D. Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy Curr Cancer Ther Rev 2 3 2006 271 279 19936034 162 Kuter D.J. Managing thrombocytopenia associated with cancer chemotherapy Oncology 29 4 2015 282 294 25952492 163 Manikandan R. Kumar S. Dorairajan L.N. Hemorrhagic cystitis: a challenge to the urologist Indian J Urol 26 2 2010 159 166 20877590 164 Horie S. Oya M. Nangaku M. Guidelines for treatment of renal injury during cancer chemotherapy 2016 Clin Exp Nephrol 22 1 2018 210 244 28856465 165 Maor Y. Malnick S. Liver injury induced by anticancer chemotherapy and radiation therapy Int J Hepatol 2013 2013 815105 23970972 166 Yeh E.T. Tong A.T. Lenihan D.J. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management Circulation 109 25 2004 3122 3131 15226229 167 Schover L.R. van der Kaaij M. van Dorst E. Creutzberg C. Huyghe E. Kiserud C.E. Sexual dysfunction and infertility as late effects of cancer treatment EJC Suppl 12 1 2014 41 53 26217165 168 Voznesensky M. Annam K. Kreder K.J. Understanding and managing erectile dysfunction in patients treated for cancer J Oncol Pract 12 4 2016 297 304 27072383 169 Mitchell T. Turton P. 'Chemobrain': concentration and memory effects in people receiving chemotherapy - a descriptive phenomenological study Eur J Cancer Care 20 4 2011 539 548 170 Moore H.C. An overview of chemotherapy-related cognitive dysfunction, or ‘chemobrain Oncology 28 9 2014 797 804 25224480 171 Dutta V. Chemotherapy, neurotoxicity, and cognitive changes in breast cancer J Cancer Res Therapeut 7 3 2011 264 269 172 Omoti A. Omoti C. Ocular toxicity of systemic anticancer chemotherapy Pharm Pract 4 2006 55 59 173 Al-Tweigeri T. Nabholtz J.M. MacKey J.R. Ocular toxicity and cancer chemotherapy A review. Cancer. 78 7 1996 1359 1373 8839540 174 Curigliano G. Cardinale D. Suter T. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Ann Oncol 23 Suppl 7 2012 vii155 vii166 22997448 175 Cohen J.D. Li L. Wang Y. Detection and localization of surgically resectable cancers with a multi-analyte blood test Science 359 6378 2018 926 930 29348365 176 Alix-Panabières C. Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy Cancer Discov 6 5 2016 479 491 26969689 177 Li L. Gao R. Yu Y. Tumor suppressor activity of miR-451:identification of CARF as a new target Sci Rep 8 1 2018 375 29321561 178 Shohdy K.S. West H.J. Circulating tumor DNA testing-liquid biopsy of a cancer JAMA Oncol 6 5 2020 792 32215604 179 Vivek R. Thangam R. NipunBabu V. Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy ACS Appl Mater Interfaces 6 9 2014 6469 6480 24780315 180 Alley S.C. Okeley N.M. Senter P.D. Antibody-drug conjugates: targeted drug delivery for cancer Curr Opin Chem Biol 14 4 2010 529 537 20643572 181 Wang X. Wang Y. Chen Z.G. Shin D.M. Advances of cancer therapy by nanotechnology Cancer Res Treat 41 1 2009 1 11 19688065 182 Firer M.A. Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies J Hematol Oncol 5 2012 70 23140144 183 Kutova O.M. Guryev E.L. Sokolova E.A. Alzeibak R. Balalaeva I.V. Targeted delivery to tumors: multidirectional strategies to improve treatment efficiency Cancers 11 1 2019 68 30634580 184 Cho K. Wang X. Nie S. Chen Z.G. Shin D.M. Therapeutic nanoparticles for drug delivery in cancer Clin Cancer Res 14 5 2008 1310 1316 18316549 185 Rosenblum D. Joshi N. Tao W. Karp J.M. Peer D. Progress and challenges towards targeted delivery of cancer therapeutics Nat Commun 9 1 2018 1410 29650952 186 Sutradhar K.B. Amin M.L. Nanotechnology in cancer drug delivery and selective targeting ISRN Nanotechnol 2014 2014 939378 187 Lammers T. Kiessling F. Ashford M. Hennink W. Crommelin D. Storm G. Cancer nanomedicine: is targeting our target? Nat Rev Mater 1 9 2016 16069 27668091 188 El-Readi M.Z. Althubiti M.A. Cancer nanomedicine: a new era of successful targeted therapy J Nanomater 2019 2019 4927312 189 Dias-Santagata D. Akhavanfard S. David S.S. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine EMBO Mol Med 2 5 2010 146 158 20432502 190 Dong L. Wang W. Li A. Clinical next generation sequencing for precision medicine in cancer Curr Genom 16 4 2015 253 263 191 Fedorenko I.V. Gibney G.T. Sondak V.K. Smalley K.S.M. Beyond BRAF: where next for melanoma therapy? Br J Cancer 112 2 2015 217 226 25180764 192 Zaman A. Wu W. Bivona T.G. Targeting oncogenic BRAF: past, present, and future Cancers 11 8 2019 1197 31426419 193 André F. Ciruelos E. Rubovszky G. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer N Engl J Med 380 20 2019 1929 1940 31091374 194 Kalra R.S. Bapat S.A. Proteomics to Predict Loss of RXR-γ during Progression of Epithelial Ovarian Cancer. Methods in Molecular Biology. New York, NY 2019 Springer New York 1 14 195 Soda M. Choi Y.L. Enomoto M. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 7153 2007 561 566 17625570 196 Hyman D.M. Puzanov I. Subbiah V. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations N Engl J Med 373 8 2015 726 736 26287849 197 Babina I.S. Turner N.C. Advances and challenges in targeting FGFR signalling in cancer Nat Rev Cancer 17 5 2017 318 332 28303906 198 Tutt A. Robson M. Garber J.E. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 9737 2010 235 244 20609467 199 Fong P.C. Boss D.S. Yap T.A. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2 2009 123 134 19553641 200 Chaudhary A. Kalra R.S. Huang C. Prakash J. Kaul S.C. Wadhwa R. 2, 3-dihydro-3β-methoxy withaferin-A protects normal cells against stress: molecular evidence of its potent cytoprotective activity J Nat Prod 80 10 2017 2756 2760 29043807 201 Friedman A.A. Letai A. Fisher D.E. Flaherty K.T. Precision medicine for cancer with next-generation functional diagnostics Nat Rev Cancer 15 12 2015 747 756 26536825 202 de la Fuente-Núñez C. Silva O.N. Lu T.K. Franco O.L. Antimicrobial peptides: role in human disease and potential as immunotherapies Pharmacol Ther 178 2017 132 140 28435091 203 Felício M.R. Silva O.N. Gonçalves S. Santos N.C. Franco O.L. Peptides with dual antimicrobial and anticancer activities Front Chem 5 2017 5 28271058 204 Hilchie A.L. Hoskin D.W. Power Coombs M.R. Anticancer activities of natural and synthetic peptides Adv Exp Med Biol 1117 2019 131 147 30980357 205 Mwangi J. Hao X. Lai R. Zhang Z.Y. Antimicrobial peptides: new hope in the war against multidrug resistance Zool Res 40 6 2019 488 505 31592585 206 Qin Y. Qin Z.D. Chen J. From antimicrobial to anticancer peptides: the transformation of peptides Recent Pat Anti-Cancer Drug Discov 14 1 2019 70 84 207 Lei J. Sun L. Huang S. The antimicrobial peptides and their potential clinical applications Am J Transl Res 11 7 2019 3919 3931 31396309 208 Roudi R. Syn N.L. Roudbary M. Antimicrobial peptides as biologic and immunotherapeutic agents against cancer: a comprehensive overview Front Immunol 8 2017 1320 29081781 209 Tornesello A.L. Borrelli A. Buonaguro L. Buonaguro F.M. Tornesello M.L. Antimicrobial peptides as anticancer agents: functional properties and biological activities Molecules 25 12 2020 2850 32575664 210 Khare T. Anand U. Dey A. Exploring phytochemicals for combating antibiotic resistance in microbial pathogens Front Pharmacol 12 2021 720726 34366872 211 van Harten R.M. van Woudenbergh E. van Dijk A. Haagsman H.P. Cathelicidins: immunomodulatory antimicrobials Vaccines 6 3 2018 63 30223448 212 Wang G. Narayana J.L. Mishra B. Design of Antimicrobial Peptides: Progress Made with Human Cathelicidin LL-37. Advances in Experimental Medicine and Biology 2019 Springer Singapore Singapore 215 240 213 Fabisiak A. Murawska N. Fichna J. LL-37:cathelicidin-related antimicrobial peptide with pleiotropic activity Pharmacol Rep 68 4 2016 802 808 27117377 214 Chen X. Ji S. Si J. Human cathelicidin antimicrobial peptide suppresses proliferation, migration and invasion of oral carcinoma HSC-3 cells via a novel mechanism involving caspase-3 mediated apoptosis Mol Med Rep 22 6 2020 5243 5250 33174023 215 Porter R.J. Murray G.I. Alnabulsi A. Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8+ T cell infiltrate J Pathol Clin Res 7 5 2021 495 506 33988317 216 Wang J. Cheng M. Law I.K.M. Ortiz C. Sun M. Koon H.W. Cathelicidin suppresses colon cancer metastasis via a P2RX7-dependent mechanism Mol Ther Oncolytics 12 2019 195 203 30847383 217 Biswaro L.S. da Costa Sousa M.G. Rezende T.M.B. Dias S.C. Franco O.L. Antimicrobial peptides and nanotechnology, recent advances and challenges Front Microbiol 9 2018 855 29867793 218 Niemirowicz K. Prokop I. Wilczewska A.Z. Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells Int J Nanomed 10 2015 3843 3853 219 Fan R. Tong A. Li X. Enhanced antitumor effects by docetaxel/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer Int J Nanomed 10 2015 7291 7305 220 Chauhan S. Dhawan D.K. Saini A. Preet S. Antimicrobial peptides against colorectal cancer-a focused review Pharmacol Res 167 2021 105529 33675962 221 Dolkar T. Trinidad C.M. Nelson K.C. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: a detailed examination of the clinicopathologic features J Cutan Pathol 45 7 2018 539 544 29665030 222 Divyashree M. Mani M.K. Reddy D. Clinical applications of antimicrobial peptides (AMPs):where do we stand now? Protein Pept Lett 27 2 2020 120 134 31553285 223 Karlitepe A. Ozalp O. Avci C.B. New approaches for cancer immunotherapy Tumour Biol 36 6 2015 4075 4078 25934338 224 Weiner L.M. Murray J.C. Shuptrine C.W. Antibody-based immunotherapy of cancer Cell 148 6 2012 1081 1084 22424219 225 Vigneron N. Human tumor antigens and cancer immunotherapy BioMed Res Int 2015 2015 948501 26161423 226 Kim I. Sanchez K. McArthur H.L. Page D. Immunotherapy in triple-negative breast cancer: present and future Curr Breast Cancer Rep 11 4 2019 259 271 227 Marra A. Viale G. Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era BMC Med 17 1 2019 90 31068190 228 Sambi M. Bagheri L. Szewczuk M.R. Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates JAMA Oncol 2019 2019 4508794 229 Paz-Ares L. Luft A. Vicente D. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer N Engl J Med 379 21 2018 2040 2051 30280635 230 Finn O.J. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic Cancer Immunol Res 2 8 2014 708 713 25092812 231 Pérez-García J. Soberino J. Racca F. Gion M. Stradella A. Cortés J. Atezolizumab in the treatment of metastatic triple-negative breast cancer Expet Opin Biol Ther 20 9 2020 981 989 232 Reddy S.M. Carroll E. Nanda R. Atezolizumab for the treatment of breast cancer Expert Rev Anticancer Ther 20 3 2020 151 158 32067545 233 Cyprian F.S. Akhtar S. Gatalica Z. Vranic S. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: a new clinical paradigm in the treatment of triple-negative breast cancer Bosn J Basic Med Sci 19 3 2019 227 233 30915922 234 Ledford H. Engineered cell therapy for cancer gets thumbs up from FDA advisers Nature 547 7663 2017 270 28726836 235 Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review) Int J Oncol 54 2 2019 407 419 30570109 236 Vanneman M. Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment Nat Rev Cancer 12 4 2012 237 251 22437869 237 Hughes P.E. Caenepeel S. Wu L.C. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer Trends Immunol 37 7 2016 462 476 27216414 238 Grosser R. Cherkassky L. Chintala N. Adusumilli P.S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors Cancer Cell 36 5 2019 471 482 31715131 239 Chiossone L. Dumas P.Y. Vienne M. Vivier E. Natural killer cells and other innate lymphoid cells in cancer Nat Rev Immunol 18 11 2018 671 688 30209347 240 Anyaegbu C.C. Lake R.A. Heel K. Robinson B.W. Fisher S.A. Chemotherapy enhances cross-presentation of nuclear tumor antigens PLoS One 9 9 2014 e107894 25243472 241 Konstantinopoulos P.A. Cheng S.C. Wahner Hendrickson A.E. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial Lancet Oncol 21 7 2020 957 968 32553118 242 Reck M. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer Immunotherapy 10 2 2018 93 105 29145737 243 Kang C. Syed Y.Y. Atezolizumab (in combination with nab-paclitaxel):a review in advanced triple-negative breast cancer Drugs 80 6 2020 601 607 32248356 244 Allard B. Allard D. Buisseret L. Stagg J. The adenosine pathway in immuno-oncology Nat Rev Clin Oncol 17 10 2020 611 629 32514148 245 Pasquini S. Contri C. Borea P.A. Vincenzi F. Varani K. Adenosine and inflammation: here, there and everywhere Int J Mol Sci 22 14 2021 7685 34299305 246 Franco R. Rivas-Santisteban R. Navarro G. Reyes-Resina I. Adenosine receptor antagonists to combat cancer and to boost anti-cancer chemotherapy and immunotherapy Cells 10 11 2021 2831 34831054 247 Helms R.S. Powell J.D. Rethinking the adenosine-A2AR checkpoint: implications for enhancing anti-tumor immunotherapy Curr Opin Pharmacol 53 2020 77 83 32781414 248 Yu F. Zhu C. Xie Q. Wang Y. Adenosine A2A receptor antagonists for cancer immunotherapy J Med Chem 63 21 2020 12196 12212 32667814 249 Yan W. Ling L. Wu Y. Structure-based design of dual-acting compounds targeting adenosine A2A receptor and histone deacetylase as novel tumor immunotherapeutic agents J Med Chem 64 22 2021 16573 16597 34783558 250 Churov A. Zhulai G. Targeting adenosine and regulatory T cells in cancer immunotherapy Hum Immunol 82 4 2021 270 278 33610376 251 Marks D.L. Olson R.L. Fernandez-Zapico M.E. Epigenetic control of the tumor microenvironment Epigenomics 8 12 2016 1671 1687 27700179 252 Lodewijk I. Nunes S.P. Henrique R. Jerónimo C. Dueñas M. Paramio J.M. Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy Clin Epigenet 13 1 2021 63 253 Pan X. Zheng L. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment Cell Mol Immunol 17 9 2020 940 953 32699350 254 Duan Q. Zhang H. Zheng J. Zhang L. Turning cold into hot: firing up the tumor microenvironment Trends Cancer 6 7 2020 605 618 32610070 255 Lim W.A. June C.H. The principles of engineering immune cells to treat cancer Cell 168 4 2017 724 740 28187291 256 Murciano-Goroff Y.R. Warner A.B. Wolchok J.D. The future of cancer immunotherapy: microenvironment-targeting combinations Cell Res 30 6 2020 507 519 32467593 257 Hulen T.M. Chamberlain C.A. Svane I.M. Met Ö. ACT up TIL now: the evolution of tumor-infiltrating lymphocytes in adoptive cell therapy for the treatment of solid tumors Immunology 1 3 2021 194 211 258 Newick K. O'Brien S. Moon E. Albelda S.M. CAR T cell therapy for solid tumors Annu Rev Med 68 2017 139 152 27860544 259 Singh A.K. McGuirk J.P. CAR T cells: continuation in a revolution of immunotherapy Lancet Oncol 21 3 2020 e168 e178 32135120 260 Jazirehi A.R. Molecular analysis of elements of melanoma insensitivity to TCR-engineered adoptive cell therapy Int J Mol Sci 22 21 2021 11726 34769156 261 Tan E. Gakhar N. Kirtane K. TCR gene-engineered cell therapy for solid tumors Best Pract Res Clin Haematol 34 3 2021 101285 34625228 262 Ö Met Jensen K.M. Chamberlain C.A. Donia M. Svane I.M. Principles of adoptive T cell therapy in cancer Semin Immunopathol 41 1 2019 49 58 30187086 263 Wolf B. Zimmermann S. Arber C. Irving M. Trueb L. Coukos G. Safety and tolerability of adoptive cell therapy in cancer Drug Saf 42 2 2019 315 334 30649750 264 Kaufman H.L. Maciorowski D. Advancing oncolytic virus therapy by understanding the biology Nat Rev Clin Oncol 18 4 2021 197 198 33686265 265 Ferrucci P.F. Pala L. Conforti F. Cocorocchio E. Talimogene laherparepvec (T-VEC):an intralesional cancer immunotherapy for advanced melanoma Cancers 13 6 2021 1383 33803762 266 Lu L. Jiang J. Zhan M. Targeting tumor-associated antigens in hepatocellular carcinoma for immunotherapy: past pitfalls and future strategies Hepatology 73 2 2021 821 832 32767586 267 Liu Z. Han C. Fu Y.X. Targeting innate sensing in the tumor microenvironment to improve immunotherapy Cell Mol Immunol 17 1 2020 13 26 31844141 268 Bejarano L. Jordāo M.J.C. Joyce J.A. Therapeutic targeting of the tumor microenvironment Cancer Discov 11 4 2021 933 959 33811125 269 Anand U. Tudu C.K. Nandy S. Ethnodermatological use of medicinal plants in India: from ayurvedic formulations to clinical perspectives - a review J Ethnopharmacol 284 2022 114744 34656666 270 Paul S. Chakraborty S. Anand U. Withania somnifera (L.) Dunal (Ashwagandha):a comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects Biomed Pharmacother 143 2021 112175 34649336 271 Lin S.R. Chang C.H. Hsu C.F. Natural compounds as potential adjuvants to cancer therapy: preclinical evidence Br J Pharmacol 177 6 2020 1409 1423 31368509 272 Nobili S. Lippi D. Witort E. Natural compounds for cancer treatment and prevention Pharmacol Res 59 6 2009 365 378 19429468 273 Mitra S. Anand U. Jha N.K. Anticancer applications and pharmacological properties of piperidine and piperine: a comprehensive review on molecular mechanisms and therapeutic perspectives Front Pharmacol 12 2021 772418 35069196 274 Mitra S. Anand U. Sanyal R. Neoechinulins: molecular, cellular, and functional attributes as promising therapeutics against cancer and other human diseases Biomed Pharmacother 145 2022 112378 34741824 275 Bandopadhyay S. Anand U. Gadekar V.S. Dioscin: a review on pharmacological properties and therapeutic values Biofactors 48 1 2022 22 55 34919768 276 Datta S. Ramamurthy P.C. Anand U. Wonder or evil? : multifaceted health hazards and health benefits of Cannabis sativa and its phytochemicals Saudi J Biol Sci 28 12 2021 7290 7313 34867033 277 Dutta T. Anand U. Saha S.C. Advancing urban ethnopharmacology: a modern concept of sustainability, conservation and cross-cultural adaptations of medicinal plant lore in the urban environment Conserv Physiol 9 1 2021 coab073 34548925 278 Tournilhac O. Cazin B. Leprètre S. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia Blood 103 1 2004 363 365 12969985 279 Chu E. DeVita V.T. Physician's Cancer Chemotherapy Drug Manual 2015 15th ed. 2015 Jones & Bartlett Learning Burlington, MA 280 Yerram P. Reiss S.N. Modelevsky L. Gavrilovic I.T. Kaley T. Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas J Neuro Oncol 145 1 2019 57 63 281 Karahoca M. Momparler R.L. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy Clin Epigenet 5 1 2013 3 282 Vanneste M. Huang Q. Li M. High content screening identifies monensin as an EMT-selective cytotoxic compound Sci Rep 9 1 2019 1200 30718715 283 Rycenga H.B. Long D.T. The evolving role of DNA inter-strand crosslinks in chemotherapy Curr Opin Pharmacol 41 2018 20 26 29679802 284 Samuels B.L. Bitran J.D. High-dose intravenous melphalan: a review J Clin Oncol 13 7 1995 1786 1799 7602368 285 Ma M.T. He M. Wang Y. miR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2) Cancer Lett 339 1 2013 107 115 23879965 286 Graham J. Muhsin M. Kirkpatrick P. Oxaliplatin Nat Rev Drug Discov 3 1 2004 11 12 14756144 287 Jacinto F.V. Esteller M. MGMT hypermethylation: a prognostic foe, a predictive friend DNA Repair 6 8 2007 1155 1160 17482895 288 Arrieta O. Lara-Mejía L. Zatarain-Barrón Z.L. Carboplatin plus etoposide or topotecan for small-cell lung cancer Lancet Oncol 21 9 2020 1132 1134 32888446 289 Hwang D.Y. Kim S.J. Cheong J.W. High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma Leuk Lymphoma 57 1 2016 51 57 25899401 290 D'Incalci M. Badri N. Galmarini C.M. Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment Br J Cancer 111 4 2014 646 650 24755886 291 Maltzman J.S. Koretzky G.A. Azathioprine: old drug, new actions J Clin Invest 111 8 2003 1122 1124 12697731 292 Hasanali Z.S. Saroya B.S. Stuart A. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia Sci Transl Med 7 293 2015 293ra102 293 Bonate P.L. Arthaud L. Cantrell W.R. Stephenson K. Secrist J.A. Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer Nat Rev Drug Discov 5 10 2006 855 863 17016426 294 Ricci F. Tedeschi A. Morra E. Montillo M. Fludarabine in the treatment of chronic lymphocytic leukemia: a review Therapeut Clin Risk Manag 5 1 2009 187 207 295 Mini E. Nobili S. Caciagli B. Landini I. Mazzei T. Cellular pharmacology of gemcitabine Ann Oncol 17 Suppl 5 2006 v7 v12 16807468 296 Engels F.K. Sparreboom A. Mathot R.A.A. Verweij J. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review Br J Cancer 93 2 2005 173 177 16012521 297 Cohen M.H. Johnson J.R. Massie T. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma Clin Cancer Res 12 18 2006 5329 5335 17000665 298 Cannon T. Mobarek D. Wegge J. Tabbara I.A. Hairy cell leukemia: current concepts Cancer Invest 26 8 2008 860 865 18798068 299 Wang H. Wang Y. LC-MS/MS coupled with stable isotope dilution method for the quantification of 6-thioguanine and S6-methylthioguanine in genomic DNA of human cancer cells treated with 6-thioguanine Anal Chem 82 13 2010 5797 5803 20550170 300 Sertel S. Tome M. Briehl M.M. Factors determining sensitivity and resistance of tumor cells to arsenic trioxide PLoS One 7 5 2012 e35584 22590507 301 Madaan K. Kaushik D. Verma T. Hydroxyurea: a key player in cancer chemotherapy Expert Rev Anticancer Ther 12 1 2012 19 29 22149429 302 Scripture C.D. Szebeni J. Loos W.J. Figg W.D. Sparreboom A. Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r) Cancer Biol Ther 4 5 2005 555 560 15917657 303 Alken S. Kelly C.M. Benefit risk assessment and update on the use of docetaxel in the management of breast cancer Cancer Manag Res 5 2013 357 365 24143122 304 Chan E.S. Cronstein B.N. Mechanisms of action of methotrexate Bull Hosp Jt Dis 71 Suppl 1 2013 S5 S8 305 Adjei A.A. Pharmacology and mechanism of action of pemetrexed Clin Lung Cancer 5 Suppl 2 2004 S51 S55 15117425 306 Weatherstone K. Meyer T. Streptozocin-based chemotherapy is not history in neuroendocrine tumours Targeted Oncol 7 3 2012 161 168 307 Haque A. Rahman M.A. Faizi M.S.H. Khan M.S. Next generation antineoplastic agents: a review on structurally modified vinblastine (VBL) analogues Curr Med Chem 25 14 2018 1650 1662 28464783 308 Beaver C. Vincristine minibag administration: a quality improvement project to minimize medical errors Clin J Oncol Nurs 22 6 2018 669 672 30452001 309 Mehta-Shah N. Ratner L. Horwitz S.M. Adult T-cell leukemia/lymphoma J Oncol Pract 13 8 2017 487 492 28796966 310 Altinoz M.A. Ozpinar A. Alturfan E.E. Elmaci I. Vinorelbine's anti-tumor actions may depend on the mitotic apoptosis, autophagy and inflammation: hypotheses with implications for chemo-immunotherapy of advanced cancers and pediatric gliomas J Chemother 30 4 2018 203 212 30025492 311 Jäger U. Barcellini W. Broome C.M. Diagnosis and treatment of autoimmune hemolytic Anemia in adults: recommendations from the first international consensus meeting Blood Rev 41 2020 100648 31839434 312 Kreitman R.J. Arons E. Update on hairy cell leukemia Clin Adv Hematol Oncol 16 3 2018 205 215 29742076 313 Begna K. Abdelatif A. Schwager S. Hanson C. Pardanani A. Tefferi A. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience Blood Cancer J 6 5 2016 e427 27232929 314 Palmer J. McCune J.S. Perales M.A. Personalizing busulfan-based conditioning: considerations from the American society for blood and marrow transplantation practice guidelines committee Biol Blood Marrow Transplant 22 11 2016 1915 1925 27481448 315 Ho G.Y. Woodward N. Coward J.I.G. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies Crit Rev Oncol Hematol 102 2016 37 46 27105947 316 Lee H.Z. Miller B.W. Kwitkowski V.E. U.S. food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia Clin Cancer Res 20 15 2014 3902 3907 24824310 317 Hew J. Pham D. Matthews Hew T. Minocha V. A novel treatment with obinutuzumab-chlorambucil in a patient with B-cell prolymphocytic leukemia: a case report and review of the literature J Investig Med High Impact Case Rep 6 2018 2324709618788674 318 Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy Radiol Oncol 53 2 2019 148 158 30956230 319 Raudenska M. Balvan J. Fojtu M. Gumulec J. Masarik M. Unexpected therapeutic effects of cisplatin Metallomics 11 7 2019 1182 1199 31098602 320 Casak S.J. Lemery S.J. Shen Y.L. U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia Oncol 16 1 2011 97 104 321 Jiang G. Li R.H. Sun C. Liu Y.Q. Zheng J.N. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis PLoS One 9 12 2014 e111920 25502446 322 Velho T.R. Metastatic melanoma - a review of current and future drugs Drugs Context 2012 2012 212242 24432031 323 Krauss A.C. Gao X. Li L. FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia Clin Cancer Res 25 9 2019 2685 2690 30541745 324 Blair H.A. Daunorubicin/cytarabine liposome: a review in acute myeloid leukaemia Drugs 78 18 2018 1903 1910 30511323 325 Dhillon S. Decitabine/cedazuridine: first approval Drugs 80 13 2020 1373 1378 32860582 326 Kanwal U. Irfan Bukhari N. Ovais M. Abass N. Hussain K. Raza A. Advances in nano-delivery systems for doxorubicin: an updated insight J Drug Target 26 4 2018 296 310 28906159 327 Cagel M. Grotz E. Bernabeu E. Moretton M.A. Chiappetta D.A. Doxorubicin: nanotechnological overviews from bench to bedside Drug Discov Today 22 2 2017 270 281 27890669 328 Buzdar A.U. Suman V.J. Meric-Bernstam F. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041):a randomised, controlled, phase 3 trial Lancet Oncol 14 13 2013 1317 1325 24239210 329 Hollingshead L.M. Faulds D. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer Drugs 42 4 1991 690 719 1723369 330 Matz E.L. Hsieh M.H. Review of advances in uroprotective agents for cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis Urology 100 2017 16 19 27566144 331 de Man F.M. Goey A.K.L. van Schaik R.H.N. Mathijssen R.H.J. Bins S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics Clin Pharmacokinet 57 10 2018 1229 1254 29520731 332 KuKanich B. Warner M. Hahn K. Analysis of lomustine drug content in FDA-approved and compounded lomustine capsules J Am Vet Med Assoc 250 3 2017 322 326 28117638 333 Sun J. Wei Q. Zhou Y. Wang J. Liu Q. Xu H. A systematic analysis of FDA-approved anticancer drugs BMC Syst Biol 11 Suppl 5 2017 87 28984210 334 Fox E.J. Mechanism of action of mitoxantrone Neurology 63 12 Suppl 6 2004 S15 S18 15623664 335 Ibrahim A. Hirschfeld S. Cohen M.H. Griebel D.J. Williams G.A. Pazdur R. FDA drug approval summaries: oxaliplatin Oncol 9 1 2004 8 12 336 Stein A. Arnold D. Oxaliplatin: a review of approved uses Expet Opin Pharmacother 13 1 2012 125 137 337 Mutter N. Stupp R. Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 6 8 2006 1187 1204 16925485 338 Ardizzoni A. Hansen H. Dombernowsky P. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European organization for research and treatment of cancer early clinical studies group and new drug development office, and the lung cancer cooperative group J Clin Oncol 15 5 1997 2090 2096 9164222 339 Garst J. Topotecan: an evolving option in the treatment of relapsed small cell lung cancer Therapeut Clin Risk Manag 3 6 2007 1087 1095 340 Eckardt J.R. von Pawel J. Pujol J.L. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer J Clin Oncol 25 15 2007 2086 2092 17513814 341 Kokolo M.B. Fergusson D. O'Neill J. Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma Leuk Lymphoma 55 12 2014 2712 2720 24491026 342 Barone A. Chi D.C. Theoret M.R. FDA approval summary: trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following an anthracycline-containing regimen Clin Cancer Res 23 24 2017 7448 7453 28774898 343 Rosenberg J.D. Burian C. Waalen J. Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series Blood 123 2 2014 177 183 24192579 344 Zhenchuk A. Lotfi K. Juliusson G. Albertioni F. Mechanisms of anti-cancer action and pharmacology of clofarabine Biochem Pharmacol 78 11 2009 1351 1359 19576186 345 Schmiegelow K. Al-Modhwahi I. Andersen M.K. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study Blood 113 24 2009 6077 6084 19224761 346 Dillman R.O. Pentostatin (Nipent®) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia Expert Rev Anticancer Ther 4 1 2004 27 36 14748654 347 Munshi P.N. Lubin M. Bertino J.R. 6-thioguanine: a drug with unrealized potential for cancer therapy Oncol 19 7 2014 760 765 348 Dent S. Messersmith H. Trudeau M. Gemcitabine in the management of metastatic breast cancer: a systematic review Breast Cancer Res Treat 108 3 2008 319 331 17530427 349 Moysan E. Bastiat G. Benoit J.P. Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications Mol Pharm 10 2 2013 430 444 22978251 350 Matt P. van Zwieten-Boot B. Calvo Rojas G. The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP) Oncol 16 10 2011 1451 1457 351 Alimoghaddam K. A review of arsenic trioxide and acute promyelocytic leukemia Int J Hematol Oncol Stem Cell Res 8 3 2014 44 54 25642308 352 Emadi A. Gore S.D. Arsenic trioxide - an old drug rediscovered Blood Rev 24 4–5 2010 191 199 20471733 353 Menzin A.W. King S.A. Aikins J.K. Mikuta J.J. Rubin S.C. Taxol (paclitaxel) was approved by FDA for the treatment of patients with recurrent ovarian cancer Gynecol Oncol 54 1 1994 103 7912683 354 Li J. Ren J. Sun W. Systematic review of ixabepilone for treating metastatic breast cancer Breast Cancer 24 2 2017 171 179 27491426 355 Abolmaali S.S. Tamaddon A.M. Dinarvand R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis Cancer Chemother Pharmacol 71 5 2013 1115 1130 23292116 356 Moore A.S. Nelson R.W. Henry C.J. Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989-1999) J Am Vet Med Assoc 221 6 2002 811 818 12322919 357 Said R. Tsimberidou A.M. Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies Expet Opin Drug Metabol Toxicol 10 3 2014 483 494 358 Martino E. Casamassima G. Castiglione S. Vinca alkaloids and analogues as anti-cancer agents: looking back, peering ahead Bioorg Med Chem Lett 28 17 2018 2816 2826 30122223 359 Smith G.A. Current status of vinorelbine for breast cancer Oncology (Williston Park) 9 8 1995 767 773 discussion 774, 776, 779 7577376 360 Gasparini G. Caffo O. Barni S. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study J Clin Oncol 12 10 1994 2094 2101 7931479